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1
Gestational trophoblastic disease
Gestational trophoblastic disease (GTD) comprises a spectrum of diseases arising 
from abnormal proliferation of trophoblastic tissue of the placenta. The modified 
World Health Organization classification of gestational trophoblastic disease 
broadly divides GTD into molar lesions and non-molar lesions.1 The molar lesions 
include partial and complete hydatidiform moles and invasive moles. The nonmolar 
lesions include choriocarcinoma, placental site trophoblastic tumour (PSTT), epithelioid 
trophoblastic tumour (ETT), and miscellaneous trophoblastic lesions including 
exaggerated placental site and placental site nodule. However, this does not provide 
a distinction between malignant or non-malignant disease. Clinically, GTD can be 
divided on the one hand into benign trophoblastic lesions including exaggerated 
placental site, placental site nodule and hydatidiform moles and trophoblastic 
neoplasia on the other. 
 Hydatidiform moles (HMs) are abnormally developing pregnancies characterized 
by hydropic swelling of the villi and trophoblastic hyperplasia with or without development 
of a foetus. They are usually benign, but may acquire malignant potential. HMs are 
classified as complete hydatidiform mole (CHM) or partial hydatidiform mole (PHM). 
PHMs are usually triploid, having two paternal and one maternal set of chromosomes, 
whereas CHMs are diploid and androgenetic, having two paternal chromosome sets.2 
In most patients, HM regresses spontaneously after suction curettage of the molar 
tissue from the uterus. However, in 15% of CHM and 0.5-6.6% of PHM trophoblastic 
tissue remains active after evacuation of the mole as shown by persistent high or even 
rising human chorionic gonadotrophin (hCG) concentrations in blood.3-5 
 According to the criteria of the International Federation of Gynecology and 
Obstetrics (FIGO), post-hydatidiform mole trophoblastic neoplasia (GTN) is defined as 
1) a plateau in weekly serum hCG concentrations for four consecutive measurements, 
2) an increase in serum hCG levels in three weekly consecutive measurements, 
3) persistence of detectable hCG levels for more than 6 months after evacuation, 
and 4) the presence of a histologic diagnosis of choriocarcinoma.6 In the Netherlands, 
an additional criterion was added to this definition in 1993. At least one of the values 
should exceed the 95th percentile of the hCG regression corridor of uneventful 
decline as constructed by Yedema et al. 7 
Gestational trophoblastic neoplasia (GTN)
Gestational trophoblastic neoplasia (GTN) represents a unique group of tumours 
that include invasive moles, choriocarcinoma, PSTT and the rare ETT.8 Invasive moles 
occupy a special position within the spectrum of GTN. Invasive moles are clinically 
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considered as gestational trophoblastic neoplasia because they can locally invade 
and distantly metastasise, but biologically they represent abnormally formed 
placental tissues rather than true neoplasia.8 An invasive mole is a hydatidiform 
mole in which hydropic villi invade the myometrium or blood vessels or, more rarely, 
are deported to extra uterine sites.1 Invasion can range from superficial penetration to 
extension through the wall, with perforation or involvement of the broad ligament.1 
Extra uterine molar disease is characterised by the presence of molar villi within 
blood vessels without invasion of adjacent tissue. Therefore this process is called 
deportation rather than metastasis.9 Invasive moles may regress spontaneously, and 
the risk of progression of invasive mole to choriocarcinoma appears to be no greater 
than that of progression from a non-invasive HM.9 
 Invasive mole must distinguished from choriocarcinoma, the latter being a 
highly malignant tumour. Approximately 50 percent of all cases of gestational cho-
riocarcinoma develop following a hydatidiform mole, 25 percent are following a 
spontaneous abortion or ectopic pregnancy, and 25 percent are following a term 
pregnancy.10 Both invasive mole and choriocarcinoma after a HM are manifested by 
a plateau or elevation in the serum hCG concentration. Consequently, clinically it is 
often not possible to distinguish between these lesions. However, histopathologi-
cally, choriocarcinoma should not be diagnosed in the presence of chorionic villi.1 
PSTT arises from intermediate trophoblast, unlike choriocarcinoma, which arises 
from villous trophoblast. PSTT grow more slowly, metastasise later, more commonly 
involve lymph-nodes and produce less hCG than choriocarcinomas.11 PSTT should be 
suspected if hCG concentrations are low for the volume of disease present on 
imaging and hCG free β-subunit values are high.11;12 The term ETT was introduced to 
describe an unusual type of trophoblastic tumour that is distinct from PSTT and cho-
riocarcinoma with features resembling a carcinoma.1;13 The frequent location of ETT 
in the low uterine segment and endocervix, as well as the epithelioid appearance of 
ETT, can lead to confusion with squamous cell carcinoma.14 GTN can occur after any 
type of antecedent pregnancy, including HM, non-molar abortions, ectopic 
pregnancies and term live births.15 The most frequent antecedent pregnancy is a 
hydatidiform mole. It is usually unknown whether GTN after a HM represents an 
invasive hydatidiform mole, choriocarcinoma or PSTT, since histological confirmation 
at the time of rising hCG is only occasionally obtained as the disease is usually 
eliminated with chemotherapy without surgery.8;16 A biopsy is discouraged since it 
can cause life-threatening haemorrhage, and a second curettage is usually not 
recommended, since it is only curative in a limited number of patients and bears the 
risk of uterine perforation, although it might be beneficial in some patients with 
low-risk GTN and reduce the number of courses of chemotherapy required for serum 
hCG normalisation.16-19 A prospective randomised controlled trial would be required 
to investigate the true curative effect of a second curettage. 
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Management of GTN
When the diagnosis of GTN is established, thorough assessment of the extent of 
disease as well as an evaluation for risk factors should be performed. A chest x-ray is 
essential, since pulmonary metastases are common. Chest CT is not needed when 
the chest x-ray is normal, since discovery of micrometastases does not affect 
outcome.20 However, recent studies showed that lung involvement on CT imaging 
(but not on chest x-ray) may predict the need to switch to second-line chemotherapy.21 
Nevertheless it is chest x-rays that are used for counting the number of lung 
metastases to evaluate the risk score.6 In patients with vaginal or lung metastases 
or with pathologic diagnosis of choriocarcinoma, a CT scan of the abdomen including 
the liver and MRI of the brain is indicated.11;22 
 Patients with GTN are classified as having low-risk or high-risk disease using the 
modified WHO prognostic scoring system as adapted by FIGO (Table 1).6 Risk factors 
that are taken into account include age, antecedent pregnancy, interval from index 
pregnancy in months, pre-(chemotherapeutic)treatment serum hCG concentration 
in IU/L, largest tumour size including the uterus, site and number of metastases, and 
previous failed chemotherapy. Each risk factor is given a score of 0, 1, 2 or 4. Patients 
with a combined prognostic score under 7 are considered low-risk and can usually be 
treated using single-agent chemotherapy. A total prognostic score of 7 or more is 
considered a high-risk score. These patients are more likely to develop resistance to 
methotrexate (MTX), and are therefore treated with multi-agent chemotherapy. In 
the Netherlands, since 1983, a clinical classification system is used proposed by the 
Table 1  Modified WHO prognostic scoring system for GTN as adapted by FIGO
Scores 0 1 2 4
Age (years) <40 ≥40 – –
Antecedent pregnancy mole abortion term –
Interval months from index pregnancy <4 4–6 7–12 >12
Pre-treatment serum hCG (IU/L) <103 103–104 104–105 >105
Largest tumour size (including uterus) – 3–4 cm ≥5 cm –
Site of metastases lung spleen, 
kidney
gastro-
intestinal
liver, brain
Number of metastases – 1–4 5–8 >8
Previous failed  chemotherapy – – single drug 2 or more 
drugs
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Dutch Working Party on Trophoblastic Disease (Table 2).23 This system defines 
high-risk disease as presence of one or more of the following features: insufficient 
response to single-agent chemotherapy; metastases in more than one organ; 
metastasis in liver, spleen, kidneys, gastro-intestinal tract, bones or brain; antecedent 
term pregnancy; and an interval of more than 12 months between the end of the 
antecedent pregnancy and the start of treatment. Absence of all of these features is 
defined as low-risk disease.
In the Netherlands, patients with GTN are treated in different referral hospitals with 
the Dutch Working Party on Trophoblastic Disease, founded in 1971, having a 
registering and advisory function. Treatment of low-risk disease consists of 
single-agent chemotherapy. The most widely used chemotherapy drugs are MTX 
and actinomycin D. In general, the 5-day MTX or actinomycin D protocols 
(intramuscular or intravenous (iv) push daily for 5 days every other week) and the 
8-day MTX-folinic acid regimen are most effective.24 In the Netherlands, low-risk 
patients receive intramuscular MTX (1 mg/kg) on days 1, 3, 5 and 7 alternating with 
oral folinic acid (FA) 15 mg on days 2, 4, 6, and 8, repeated every two weeks. Low-risk 
GTN is extremely responsive to chemotherapy, and short-term toxicity of MTX is 
lower than that of actinomycin D.23;25;26 Treatment continues until the hCG level is 
normal and then for a further consolidation period. In patients who develop 
Table 2   Risk classification of GTN by the Dutch Working Party on Trophoblastic 
Disease
Low-risk GTN Demands all of the following conditions: 
1.  Antecedent pregnancy: hydatidiform mole or abortion* 
2.  No metastases or metastases in vagina or lung  
3.  No previous chemotherapy 
4.  Interval between evacuation and start of chemotherapy less 
     than 12 months 
High-risk GTN Demands one or more of the following conditions:
1.  Failure of previous (mono-) chemotherapy  
2.  Metastases in more than one site (outside the uterus)
3.  Metastases in one or more of the following organs: 
     liver, spleen, kidney, gastrointestinal tract, bones or brain 
4.  Antecedent pregnancy: term
5.  Interval between end of antecedent pregnancy and start of 
     chemotherapy more than 12 months
* There is no consensus on classification of non-molar abortion as low- or high-risk disease
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resistance to MTX or relapse after completing MTX therapy, the level of hCG indicates 
the mode of further treatment. Patients with a low serum hCG level and no signs of 
metastatic disease can be treated with actinomycin D, whereas patients with high 
hCG levels should be switched to multi-agent chemotherapy in the form of EMA/CO 
(etoposide, MTX and actinomycin D, alternating with cyclophosphamide and 
vincristine).26 The current Dutch guideline for GTN formulated by the Working Group 
Oncologic Gynaecology states that treatment with actinomycin D can be considered 
if the serum hCG is lower than 100 IU/L.23 However, a cut-off for the serum hCG 
concentration in ng/ml (measured with the Nijmegen radioimmunoassay) has not 
been formulated. Initially in the UK, in patients who developed MTX resistance or 
toxicity with a serum hCG concentration of <100 IU/L, therapy was changed to 
single-agent actinomycin D (0.5 mg intravenously daily for five days, repeated every 
two weeks). For patients whose hCG was greater than 100 IU/L at the time of 
developing MTX resistance or toxicity, EMA/CO treatment was used.26 Nowadays, 
the UK gestational trophoblastic disease service has increased the hCG concentration 
at which multi-agent chemotherapy is started to > 300 IU/L, to reduce the number 
of women being exposed to greater toxicity.11 
 Patients with high-risk disease are primarily treated with EMA/CO. This regimen 
is repeated every two weeks until disease remission and then continued for an 
additional three cycles. Management of PSTT differs from that of other forms of 
GTN. A hysterectomy with sampling of pelvic lymph nodes is the primary mode of 
treatment in patients with non-metastatic disease.27 Patients with metastatic PSTT 
require more aggressive treatment with an additional platinum-containing 
chemotherapy regimen such as EMA/EP (etoposide, MTX and actinomycin D, 
alternated with etoposide and cisplatin) until 8 weeks of normal hCG concentrations 
are recorded.11;28 The EMA/EP regimen is different as compared to EMA/CO as 
etoposide and actinomycin D are administered for one day rather than two, and cy-
clophosphamide and vincristine are replaced by etoposide and cisplatin. EMA/EP is 
the most commonly used regimen for patients resistant to EMA/CO or with disease 
relapse after initially achieving disease remission with EMA/CO.29 A hysterectomy 
should also be considered in women with chemotherapy-resistant disease. 
Disease incidence 
Before attempting to contribute in optimising the management of GTN, we would 
like to gain insight into how many patients are affected by GTD in the Netherlands. 
In North America and Europe, rates of HM are about 0.5 to 1 per 1000 pregnancies. 
Higher frequencies have been reported for some areas of Asia and the Middle East, 
with rates ranging from 1 to 12 per 1000 pregnancies.30-32 Incidence rates for chorio-
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carcinoma range from 2-7 per 100,000 pregnancies in Europe and North America, to 
5-200 per 100,000 pregnancies in Asia.33;34
 The variation in worldwide incidence rates results in part from discrepancies 
between population-based and hospital-based data. Many older studies used 
hospital-based data, which tend to show a higher incidence of GTD than those 
reported in population-based studies. This may be due to underestimation of the 
population at risk (e.g. the number of pregnancies, deliveries or live births) in 
hospital-based studies. In the Netherlands, patients with GTD are registered at the 
Dutch Central Registry for Hydatidiform Moles (DCRHM) residing at the Radboud 
University Nijmegen Medical Centre (RUNMC). This voluntary registry serves as an 
epidemiological database and provides a national hCG assay service to 
gynaecologists, and currently contains 4,190 records of patients with GTD. This 
corresponds to an average of 120 GTD patients registered per year. Since registration 
is voluntary, registration bias may occur and uncertainty exists on the completeness 
of the registration. Currently, no population-based data on the incidence of GTD are 
available from the Netherlands. 
Prediction of GTN
HCG follow-up after evacuation of hydatidiform moles is essential to identify 
patients requiring chemotherapeutic treatment for post-molar GTN. However, 
post-molar GTN seems to be pre-programmed, since delayed evacuation at an 
increased gestational age does not increase the risk of requiring chemotherapeutic 
treatment.35 Therefore many investigators have attempted to predict at an early 
stage which patients will go into disease remission and which patients will develop 
malignant disease. Most of this research has focused on hCG in serum 36-38, but also 
investigators have studied whether urine hCG could be reliably used to predict 
disease remission.39 Some authors attempted to find absolute serum hCG levels 
predictive of outcome.40 Others attempted to predict post-molar GTN using ratios 
of two hCG values in serum.41-43 Also, normograms were developed for normal hCG 
regression after evacuation by plotting serum hCG values against time for patients 
that showed spontaneous disease remission and patients that developed GTN.7;44-46 
Although these methods aid in earlier diagnosis of GTN, still no generally accepted 
method is available for prediction of GTN prior to the clinical detection of GTN by 
FIGO 2000 criteria. 
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Treatment of  low-risk GTN
As mentioned before, low-risk GTN patients are treated with MTX until the hCG 
level is normal and then for a further consolidation period. The number of courses of 
MTX administered after normalisation of serum hCG levels may influence the risk of 
disease relapse.47;48 Previous studies showed that relapse rates in low-risk GTN 
patients range from 1.8 to 8.1%.26;49-52 However, studies on relapse rates often 
combined relapse rates of low- and high-risk disease or included relapse after 
subsequent second-line chemotherapy because of resistance to MTX.48;49;53 In 74 
low-risk GTN patients treated with MTX/FA in the Netherlands a relapse rate of 8.1% 
was found.50 McNeish et al. studied 324 low-risk GTN patients treated with MTX/FA 
in the UK and found a relapse rate of only 3.4%.26 Definitions of relapse differed 
between these studies, and a comparative study on the influence of different 
numbers of consolidation courses on relapse rates has not been carried out.
Treatment of high-risk GTN
Although survival of patients with low-risk disease is almost 100% 26;51, patients still 
die from high-risk disease, with reported survival rates of 87 to 91% after treatment 
with EMA/CO and adjuvant cisplatin-based chemotherapy, surgery and 
radiotherapy.54-57 Although the group of patients who died from GTN provides a 
unique insight in what can be learnt for future management of GTN, literature on 
fatal cases of GTN is limited and mostly dated.58-60 Lurain et al. studied 48 patients 
who died from invasive mole or choriocarcinoma from 1962 to 1979 at the 
Trophoblastic Disease Centre of Northwestern University.58 Mazur et al. studied the 
31 autopsied cases within this group.59 Five patients presented with a fulminant 
clinical course and died before any chemotherapy could be given. Overall, tumour 
haemorrhage and pulmonary insufficiency were the most common causes of death. 
Moodley et al. described more recently a profile of mortality among women with 
GTD infected with the human immunodeficiency virus (HIV).60 Of the 15 deaths, 5 
patients were admitted in very poor general condition precluding the administration 
of chemotherapy. Five HIV-infected patients and 5 non-HIV infected patients 
received chemotherapy. The causes of death in the 10 patients included widespread 
disease, multi-organ failure and toxicity due to chemotherapy. An overview of 
patients who died from GTN despite more up-to-date treatment standards would 
provide further information on potential areas to further improve current practice.
 Today, the most widely accepted initial treatment for high-risk trophoblastic 
tumour is EMA/CO chemotherapy introduced in 1979 by Newlands and Bagshawe.61 
EMA/CO (day 1: etoposide 100  mg/m2, actinomycin D 0.5 mg iv bolus MTX 300  mg/
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m2; day 2: etoposide 100  mg/m2, actinomycin D 0.5 mg/m2, folinic acid rescue 15 mg 
every 12 hours for four doses; day 8: etoposide 100  mg/m2, vincristine 1 mg/m2, cy-
clophosphamide 600 mg/m2) is a relatively well-tolerated regimen. In a series of 45 
patients treated with EMA/CO, alopecia was universal, but there was no life-threat-
ening toxicity.55 However, EMA/CO is associated with long-term toxicity in the form 
of secondary malignancy and an earlier start of menopause.62;63 Triple therapy with 
MAC (MTX, actinomycin D plus either chlorambucil (original regimen) or cyclophos-
phamide (modified regimen)) was once the preferred first-line treatment for 
high-risk patients, but this passed out of use because of low remission rates of 51 to 
73%.64;65 When the combination of cyclophosphamide, hydroxyurea, actinomycin D, 
MTX with folinic acid, vincristine, and doxorubicin (CHAMOCA) was compared to 
MAC in a randomized trial, the remission rate was lower and toxicity was higher 
with CHAMOCA compared to MAC.65 A few years earlier the successful use of 
cisplatin was reported in patients with disseminated testicular carcinoma, including 
testicular choriocarcinoma, and the first preliminary studies on the use of cisplatin 
is gestational choriocarcinoma were reported.66-68 In 1982, a multi-agent 
chemotherapy schedule (EMACP, day 1: etoposide 100 mg/m2, MTX 100 mg/m2 iv 
bolus; 200 mg/m2 cyclophosphamide 600 mg/m2; day 2: etoposide 100 mg/m2, 
actinomycin D 0.6 mg/m2; day 3: etoposide 100 mg/m2; day 4: etoposide 100 mg/m2, 
cisplatin 60 mg/m2; day 5: etoposide 100  mg/m2) was designed by the Dutch 
Working Party on Trophoblastic Disease, aiming to compose a schedule that could 
be repeated frequently with a short interval between two courses, causing less my-
elosuppression than CHAMOCA and containing the new agents etoposide and 
cisplatin. However, due to the toxicity associated with cisplatin, on an international 
level preference was given to an initial treatment regimen without cisplatin for 
high-risk patients. Although multi-agent chemotherapy in the form of EMACP was 
applied in the Netherlands for an extensive period of time, it has not been compared 
to EMA/CO chemotherapy in the treatment of patients with high-risk GTN. 
Prediction of treatment failure in high-risk GTN patients 
Not all patients are cured with initial multi-agent chemotherapy in the form of 
EMA/CO or EMACP. Some patients develop resistance to multi-agent chemotherapy 
during treatment, whereas others achieve complete remission but develop disease 
relapse afterwards. Patients with chemo resistant GTN have a worse outcome 
compared with patients with relapsed GTN.69 For these patients, treatment options 
are limited. Salvage chemotherapy in the form of EMA/EP alone or combined with 
salvage surgery is reported to achieve remission in 70 to 88% of patients resistant to 
EMA/CO.29;54;70 Early identification of patients resistant to multi-agent chemotherapy 
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is highly important, since these patients are at risk for a fatal outcome. Previous 
studies determined predictive factors of a poor outcome.71-73 Factors determined to 
significantly influence the chance of resistance to initial chemotherapeutic 
treatment  (requiring additional treatment) were presence of metastatic disease, 
metastases to other sites than the lung or vagina, prior unsuccessful chemotherapy 
and duration of disease for more than 4 months, although these factors were 
analysed for initial single-agent chemotherapy for low-risk disease and initial 
multi-agent chemotherapy for patients with metastatic high-risk disease combined.72 
Kim et al. found that a tumour age of more than 12 months, metastases to more 
than two organs and incomplete previous treatment were independent risk factors 
for poor prognosis.71 In patients with two and three of these factors, the death rates 
were 17.7 and 56.6%, respectively. Previously, van Trommel et al. developed a 
normogram for the regression of hCG in the treatment of low-risk GTN with 
single-agent MTX to identify resistance to MTX at an early stage. This normogram 
allows the identification of 50% of patients needing alternative therapy with a 
specificity of 97.5% before the fourth course of MTX.74 However, a common definition 
for resistance to multi-agent chemotherapy is still lacking. More importantly, no 
method is available to predict resistance to multi-agent chemotherapy.
Outline of the thesis
The main aim of the present thesis was to further optimise the management of 
patients with GTN by attempting to predict post-molar GTN and resistance to 
multi-agent chemotherapy. In Chapter 2 we determine the incidence and time 
trends of GTD in the Netherlands using population-based data in order to evaluate 
the extent to which women in the Netherlands are affected by this disease. In 
Chapter 3 we propose a model based on the slope of the linear regression line of 
three consecutive serum hCG measurements in the first weeks after evacuation for 
the prediction of post-molar GTN. Early prediction of GTN allows start of treatment 
at a less advanced stage of the disease and thus contributes to a favourable outcome. 
However, despite the start of adequate treatment, some patients will develop 
resistance to chemotherapy or relapsed disease after achieving disease remission. In 
Chapter 4 we compare in a retrospective setting the relapse rates of women 
completing MTX therapy for GTN in the Netherlands and the UK. Disease relapse 
requires treatment with multi-agent chemotherapy, which, in contrast to MTX, is 
associated with an increased incidence of secondary malignancies and with the risk 
of an early menopause. Therefore an additional course of MTX would be preferred if 
this decreases the chance of developing relapsed disease. Chapter 5 reviews all 
patients who died from GTN over the last four decades in the Netherlands and aims 
20 | Chapter 1
to evaluate whether treatment was given according to the protocol or guideline at 
the time of diagnosis and to reveal possible implications for future management. 
Previously, cisplatin has been identified as an active agent for achieving complete 
remission in high-risk GTN. However, introduction of cisplatin to the treatment 
regimen may cause a higher toxicity, resulting in dose delay or dose reduction. For 
this reason in Chapter 6 we evaluate the efficiency, survival rate and complications 
of cisplatin-based combination chemotherapy (EMACP) as compared to the EMA/
CO schedule for the treatment of high-risk GTN. For patients who will not be cured 
with EMA/CO or EMACP, respectively, an early switch to EMA-EP chemotherapy of 
salvage surgery is highly important. Therefore in Chapter 7 we aim to construct a 
normogram for the hCG regression in patients with high-risk GTN successfully 
treated with EMA/CO chemotherapy in order to predict patients developing 
resistance to EMA/CO. The results presented in these chapters and possible 
implications for future management are generally discussed in Chapter 8 and 
summarised in Chapter 9.
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Abstract
Background We determined the incidence and time trends of gestational 
trophoblastic disease (GTD) in the Netherlands using population-based data.
Methods Data on patients with a pathologically confirmed diagnosis of GTD from 
1995 to 2008 were obtained from PALGA, a national archive containing all histo-
pathology reports in the Netherlands. Data on number of deliveries were obtained 
from the Database of Statistics Netherlands.
Results During the study period, 4249 GTD patients were registered. Overall 
incidence rates of hydatidiform mole (HM), choriocarcinoma and placental site 
trophoblastic tumour (PSTT) were 1.34 per 1000 deliveries, 3.1 per 100,000 deliveries, 
and 1.0 per 100,000 deliveries, respectively. Incidence rates of HM increased from 
1.02 per 1000 deliveries in 1995 to 1.56 per 1000 in 2001, an increase of 0.091 per year 
(95%CI 0.081-0.101). After 2001 incidence rates remained constant (increase per year 
-0.010, 95%CI -0.045-0.024). Maternal age and ethnicity are known to influence the 
risk of HM. Highest incidences were observed in women under 20 and over 40 years 
of age. The proportion of deliveries accounted for by women over 40 years of age 
increased from 1.5% to 2.9%, whereas women under 20 accounted for 1.5% of deliveries. 
The proportion of live births of Asian descent increased from 2.6% to 3.7%.
Conclusion The incidence of GTD in the Netherlands increased significantly from 
1995 to 2008. This can partially be explained by increased maternal age and increased 
proportion of live births of Asian descent. Part of the increase might result from 
improved diagnostic techniques. However, these factors do not seem to account for 
the total observed increase and part of the increase therefore remains unexplained.
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Introduction
Gestational trophoblastic disease (GTD) consists of a heterogeneous group of 
disorders that are characterized by an abnormal proliferation of trophoblastic tissue. 
The modified World Health Organization (WHO) classification of GTD includes 
exaggerated placental site, placental site nodule, complete and partial hydatidiform 
mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour (PSTT), 
and epithelioid trophoblastic tumour (ETT).1;2 Hydatidiform mole (HM) is the most 
common form of GTD. The reported incidence varies widely in different regions of 
the world. In North America and Europe, rates of HM are about 0.5 to 1 per 1000 
pregnancies. Higher frequencies have been reported for some areas of Asia and the 
Middle East, with rates ranging from 1 to 12 per 1000 pregnancies.3-6 As has been 
reported for HM, incidence rates for choriocarcinoma also differ markedly 
throughout the world. In Europe and North America, rates of 2 to 7 per 100,000 
pregnancies have been reported, whereas in Asia rates have been noted as high as 5 
to 200 per 100.000 pregnancies.3-5;7;8 PSTT is a rare form of GTD, with fewer than 250 
cases reported in the literature.9
 Comparisons of GTD incidence rates among different regions in the world are 
limited by the various methods used to determine rates. The variation in worldwide 
incidence rates results in part from discrepancies between population-based and 
hospital-based data.10-12 In addition, incidence rates may be based on the total 
number of pregnancies, deliveries, or live births.3;12 Furthermore, under-registration 
of GTD might occur, as was demonstrated by Flam et al.13 Their study showed that 
25% of patients with a diagnosis of HM were not included in the Swedish Cancer 
Registry. This further underlines the importance of an accurate, centralized 
registration of this disease. In the Netherlands, a unique nationwide network and 
archive was established in 1971 under the name of PALGA (‘Pathologisch Anatomisch 
Landelijk Geautomatiseerd Archief’; Pathological Anatomy National Automated 
Archive), in order to facilitate the optimal use of histopathology and cytopathology 
data for research and quality control. Since 1991, this registration has encompassed 
all sixty-four pathology laboratories in the Netherlands and has complete coverage: 
every histopathological and cytopathological diagnosis made in the Netherlands is 
entered into this registration.14 The aim of the present study is to determine incidence 
rates and time trends of GTD in the Netherlands with the use of a population-based 
database from 1995 to 2008.
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Methods
Histopathology database
The PALGA database is a national archive containing abstracts of all histopathology 
and cytopathology reports generated in the Netherlands, with a nationwide 
coverage since 1991. Abstracts of all pathology reports are generated automatically 
at the participating laboratories and transferred to the central data bank. These 
abstracts contain encrypted patient identification data (including date of birth, 
gender and the first eight characters of the patient’s family name), a summary of 
the pathology report, and a so-called PALGA diagnosis, a coded diagnosis line based 
upon standard pathology terminology. This code consists of a term indicating the 
anatomical location, type of sample and a morphological term describing the 
finding.14 The present study includes data recorded in the PALGA database between 
1995 and 2008. For each report, first initial, age, date of pathology report, summary 
text and diagnostic codes were made available.
Patient selection
A selection of the central database was obtained containing records of patients 
diagnosed with GTD. Selection was based on the following items: ’placental site 
nodule’, ‘exaggerated placental site reaction’, ‘mole’, ‘complete mole’, ‘partial mole’, 
‘invasive mole’, ‘persistent trophoblastic disease’, ‘trophoblastic proliferation’, ’cho-
riocarcinoma’, ‘metastasis choriocarcinoma’, ‘intratubular choriocarcinoma’, 
‘placental site trophoblastic tumour’ and ‘trophoblastic pseudotumour’. Epithelioid 
trophoblastic tumour is not yet recorded as a PALGA thesaurus diagnosis. These 
search terms selected 4494 abstracts. All patients with a histologically confirmed 
diagnosis of GTD were identified in the database. Revisions from abroad were 
excluded (n=5). The remaining reports were reviewed and categorized according to 
the WHO classification of GTD: exaggerated placental site or placental site nodule, 
complete mole, partial mole, invasive mole, choriocarcinoma, placental site 
trophoblastic tumour, and epithelioid trophoblastic tumour. Two categories were 
added to this classification: a category of ‘unspecified HM’ was added for moles that 
were clearly HM, but a further classification into partial or complete was not made. 
In addition, a category of ‘abortion or HM’ was added, in which those patients were 
categorized of whom the pathologist was not sure whether the specimen concerned 
a hydatidiform mole. Inconclusive reports were reviewed and classified by an expert 
pathologist, specialized in gynaecological pathology. Patients that were eventually 
not diagnosed with GTD were excluded from further analysis (n=227). Thirteen 
patients were diagnosed as having persistent trophoblastic disease (PTD). Since PTD 
is a clinical diagnosis and not a pathological diagnosis, these patients were also 
excluded from further analysis. A total of 4249 patients were included in the study. 
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The study was carried out in the Netherlands in accordance with the applicable rules 
concerning the review of research ethics committees and informed consent. 
Statistical Analyses
Incidence rates of HM, choriocarcinoma and PSTT were calculated as the number of 
patients diagnosed  in the PALGA database divided by the total number of deliveries. 
Data on the number of deliveries were obtained from Statistics Netherlands and 
included live births and stillbirths from 24 weeks gestation and onwards.15 Data on 
the descent of live births, according to the country of origin of the parents, was also 
obtained from Statistics Netherlands. Incidence rates of HM were calculated per 
1000 deliveries. Incidence rates of choriocarcinoma and PSTT were calculated per 
100,000 deliveries. Trends in the incidences over time were calculated using linear 
regression. Regression coefficients were calculated per 1000 deliveries from 1995 to 
2008. Statistical analysis was performed using SPSS software (version 16.0).
Results
Gestational trophoblastic disease
Between 1995 and 2008, a total of 4249 cases of gestational trophoblastic disease 
were registered in the Netherlands. The age of the patients ranged from 13 to 73 
years with a median age of 30.0 years. Evaluation of the pathological reports 
revealed complete and partial HM in 30.2% and 44.5% of patients, respectively. 
Patients diagnosed with a mole not further specified into a partial or complete mole 
comprised 11.6% of all GTD patients, and 8.6% were categorized as having an 
‘abortion or HM’ (Table 1). A significant trend to an increase in the overall incidence 
of GTD could be observed (increase per year 0.032, 95% CI 0.012-0.052). The 
frequency and incidence of GTD registered in the Netherlands over fourteen years is 
shown in Table 2. The annual number of GTD averaged 303 cases per year. The overall 
incidence was 1.56 per 1000 deliveries per year.
Hydatidiform mole
A total of 3,668 HMs were registered during the 14-year study period. Median 
maternal age was 30.0 years (range 13-59 years). In order to assess a possible time 
trend in the incidence of hydatidiform mole, patients were analyzed according to the 
year of diagnosis. Figure 1 shows trends in the annual incidence rates for hydatidiform 
mole over the years. The overall incidence rate in total HM (complete, partial and 
unspecified hydatidiform mole) was 1.34 per 1000 deliveries (262 cases per year). 
Incidence rates of HM increased from 1.02 per 1000 deliveries in 1995 to 1.56 per 
1000 deliveries in 2001, an increase of 0.091 per year (95% CI 0.081-0.101). Given the 
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approximately 200,000 deliveries each year in the Netherlands, this corresponds to 
an increase of 18 molar pregnancies per year. After 2001 the incidence rate remained 
constant (increase per year -0.010, 95% CI -0.045-0.024). Regression was calculated 
for several windows around 2001 and results proved to be very similar. 
 The incidence of both complete and partial HM increased across the study 
period. In complete moles, a gradual increase was observed, from 0.34 per 1000 
deliveries in 1995 to 0.63 per 1000 deliveries in 2008 (0.015 per year, 95% CI 
0.007-0.022). In partial moles, a strong increase was initially observed from 0.44 per 
1000 deliveries in 1995 to 0.82 per 1000 deliveries in 2002 (increase per year 0.061, 
95% CI 0.048-0.074), however, after this, the incidence rate in partial moles did not 
significantly change (-0.020 per year, 95% CI -0.047-0.007). In contrast, the incidence 
rate of unspecified moles gradually decreased during the study period, from 0.23 per 
1000 to 0.10 per 1000 deliveries, respectively (-0.012 per year,  95% CI   -0.015 - 
-0.008). The incidence of ‘abortion or HM’, a category where uncertainty existed 
concerning the diagnosis, remained constant throughout the years (increase 0.002 
per year, 95% CI  -0.007-0.010). Overall, in this category an incidence of 0.13 per 1000 
deliveries was observed. 
Choriocarcinoma and PSTT
During the study period, 91 cases of gestational choriocarcinoma were reported to 
the PALGA database, giving an overall incidence of 3.1 per 100,000 deliveries. Thirty 
Table 1   Frequency and incidence rate of types of gestational trophoblastic 
disease (GTD) in the Netherlands, 1995-2008
Type of GTD N Percentage Incidence rate*
EPS / placental site nodule 88 2.1 0.032
Complete HM 1285 30.2 0.470
Partial HM 1892 44.5 0.692
Invasive mole 9 0.2 0.003
Unspecified mole 491 11.6 0.180
Abortion or HM 366 8.6 0.134
Choriocarcinoma 87 2.0 0.032
PSTT 30 0.7 0.011
ETT 1 .0 0.0004
Total 4249 100 1.56
*per 1000 deliveries
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patients were diagnosed with PSTT, resulting in an overall incidence of 1.0 per 
100,000 deliveries.
Maternal age in hydatidiform mole
Figure 2 shows incidence rates of HM for different maternal age categories as a 
function of time. The highest incidences were observed in patients under 20 years of 
age and in patients over 40 years of age. An overview of all deliveries in the 
Netherlands in different age categories is given in Figure 3. The number of women 
delivering after the age of 40, as is shown on the right y-axis, increased 85%, from 
2950 in 1995 to 5469 in 2008, respectively. However, this accounts for an increase 
from 1.5% to 2.9% of the total number of deliveries. The number of deliveries in 
women younger than 20 increased from 1995 to 2001, after which the number 
returned to the same level as observed in 1995, and accounts for 1.5% of the total 
number of deliveries. Most deliveries occurred in the group of women between 30 
Table 2   Frequency and incidence rates of gestational trophoblastic disease (GTD) 
in the Netherlands by year, 1995-2008
Year Number of GTD^ Deliveries Incidence rate*
1995 229 191735 1.19
1996 243 190742 1.27
1997 266 193722 1.37
1998 293 200679 1.46
1999 326 201708 1.62
2000 352 207872 1.69
2001 355 203861 1.74
2002 322 203268 1.58
2003 331 201421 1.64
2004 289 195020 1.48
2005 279 188893 1.48
2006 338 185913 1.81
2007 319 182117 1.75
2008 307 185408 1.66
Total 4249 2732359 1.56
*per 1000 deliveries        
^ including ‘abortion or HM’
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and 35 years old. Calculating the contribution of each age category to the total 
incidence of HM shows that no age category solely caused the increase of HM 
incidence.
Figure 1   Incidence rate per 1000 deliveries for hydatidiform mole (HM) patients  
over time (1995-2008) in the Netherlands. Total HM includes complete, 
partial and unspecified HM.
Figure 2   Age-adjusted incidence rate per 1000 deliveries in hydatidiform mole 
patients. Incidence rates of HM for different maternal age categories  
are shown as a function of time.
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Ethnicity in hydatidiform mole
Since women of Asian descent are thought to have a higher risk of developing a HM, 
the influence of the number of live births from Asian descent on the total number of 
live births was analyzed. In the Netherlands, the number of live births with at least 
one parent of Asian descent increased more than 40%, from 4886 in 1995 to 6853 in 
2008. This accounts for an increase from 2.6% to 3.7% of the total number of live 
births. 
Discussion
The present study provides long-term nation-wide data on the incidence of GTD in 
the Netherlands. Studies presenting incidence rates after the early 1990s are limited. 
An overview of more recent population-based studies on the incidence of HM and 
choriocarcinoma is given in Table 3. Many older studies used hospital-based data, 
which tend to show a higher incidence of GTD than those reported in population-
based studies. This may be due to underestimation of the population at risk in 
hospital-based studies, especially in under-developed countries, since many births 
take place at home, and high-risk pregnancies or cancer cases are more likely to 
receive hospital care than are uncomplicated deliveries.12;16;17 
 Differences in reported incidence rates can also be accounted for by inaccurate 
ascertainment of the number of patients as a function of the number of gestational 
events. Different denominators, which represent the population at risk, are used in 
Figure 3   The total number of deliveries in different age categories over time  
(1995-2008) in the Netherlands.
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published studies. The preferred denominator for women at risk of GTD is ‘all women 
who have conceived’. Since this number is unknown, ratios for GTD are presented in 
relation to the number of pregnancies, deliveries, or live births. The item ‘pregnancies’ 
usually includes live-births, stillbirths, spontaneous and induced abortions, and 
ectopic pregnancies, and represents the closest approximation to the population at 
risk. ‘Deliveries’ does not take into account the number of conceptions that terminate 
because of induced or spontaneous abortion, and in addition lacks a smaller number 
of ectopic pregnancies. When the denominator ‘live births’ is used, even more 
conceptions at risk are being excluded.5;12 Because these denominators underestimate 
the size of the population at risk, the estimates of the incidence of GTD are likely to be 
too high.12 However, since the total number of deliveries is inevitably collected more 
accurately than the number of pregnancies, we used ‘deliveries’ as the denominator to 
calculate incidence rates in the present study. 
 In our study, an overall incidence rate of HM of 1.34 per 1000 deliveries was 
found. This is consistent with rates found in previous population-based studies in 
Scandinavia (1.1 per 1000 pregnancies and 1.46 per 1000 deliveries in Denmark and 
Sweden, respectively) and the United States (1.19 per 1000 pregnancies).16;18;19 Higher 
incidences have been found in Ireland17 and Japan20, with rates of 2.2 per 1000 
deliveries and 2.23 per 1000 live births, respectively. However, incidence rates in 
Japan declined substantially, hereby approaching incidence rates found in Europe 
and the United States.20;21 Flam et al. showed that there were no significant 
differences over time in the incidence of HM in Sweden.16 Interestingly, in the present 
study, incidence rates increased, from 1.02 per 1000 deliveries in 1995 to 1.56 per 
1000 deliveries in 2001, respectively, after which the incidence rate has remained 
constant. Similarly, an increasing trend in the incidence of GTD was found in 
Northern England, from 1.26 in 1991 to 1.63 per 1000 live births in 1999, respectively.22
 Concerning choriocarcinoma, an incidence of 3.1 per 100,000 deliveries was 
found in the present study. This is in accordance with data from other population-
based studies conducted in Western countries. The reported incidence was between 
2.4 and 4.0 per 100,000 deliveries in Sweden16, Denmark18, New Mexico8 and Finland7. 
In the present study, an overall incidence of PSTT of 1.0 per 100,000 deliveries was 
demonstrated. The epidemiology of PSTT is hardly described. We found no other 
studies presenting incidence rates on PSTT.
 The influence of maternal age on the risk of HM has been studied extensively.16;18;23-
29 An increase in maternal age has been proposed as a possible explanation for an 
increasing incidence of HM. Analyses of the maternal age in HM patients in our 
study revealed that the highest incidences were observed in patients under the age 
of twenty and in patients older than forty, confirming previous literature.3;22;23;28 
However, both age categories accounted for only a small percentage of the total 
number of deliveries. The increased numbers of deliveries in these age categories can, 
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therefore, only partially explain the observed 30% increase in the incidence of HM in 
the total group.
 Another explanation of the increasing incidence of HM might be found in an 
increase in women of Asian descent. Many studies have demonstrated the relation 
between ethnicity and risk of molar pregnancy.19;22;25;30 Women of Asian descent are 
thought to have two- or threefold higher rates of HM compared to Caucasian 
women.6;22 However, since the proportion of live births of Asian descent increased only 
1.1%, this can only for a small part explain the observed increase in the incidence of HM.
 To what extent epidemiological trends are a result of the improvement of 
diagnostic techniques for GTD is unknown.12 During the years, diagnostic options in 
the field of GTD significantly advanced.31 Flow cytometric DNA ploidy analysis can 
distinguish diploid complete mole or hydropic abortuses from triploid partial moles 
by analyzing a large number of random nuclei. Flow cytometry was first described in 
the PALGA records in 1994, and has since then been widely used as a rapid and easy 
test for ploidy. The introduction of flow cytometry might explain the observed 
increase of partial moles. Partial moles that were previously erroneously diagnosed 
as hydropic abortion, could since then be proven to be triploid using flow cytometry. 
Since partial moles account for an important part of the total amount of HMs, this 
might explain the increase of the incidence of total HM. With the introduction of 
p57kip2 immunohistochemistry, first mentioned in our PALGA records in 2002, a 
better differentiation between complete and partial mole has become possible. The 
p57kip2 gene is paternally imprinted and expressed from the maternal allele. Since 
complete moles lack a maternal genome, p57kip2 immunostaining is absent, whereas 
hydropic abortuses and partial moles show positive staining.32 In the present study, 
the incidence of unspecified moles significantly decreased during the study period, 
mostly after p57kip2 IHC was introduced. Simultaneously, an increase in the incidence 
of complete moles was observed, suggesting that these unspecified moles were 
mainly categorized as complete moles. However, this will not have influenced the 
overall incidence of HM since unspecified moles were also considered in the calculation 
of the overall incidence of HM. The category ‘abortion or HM’ remained constant 
throughout the years. The fact that this category of disease did not diminish with 
the introduction of new diagnostic techniques might suggest that these are in fact 
mostly non-molar pregnancies.  
 Since part of the observed increase of GTD seems to remain unexplained, 
questions may arise concerning the influence of possible shortcomings of the 
registration system used. However, the PALGA system was founded in 1971 and 
reached complete national coverage in 1991. Since our data were obtained from 1995 
onwards, this to our opinion should ensure good reporting. 
 Strengths of our study are the large series of patients with GTD that were 
analyzed. Additionally, collection of patients by means of the PALGA registry ensured 
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non-selected data. Limitations of our study are the retrospective analysis of the 
pathological abstracts and the fact that no histopathological review of the cases 
was performed.
 In conclusion, the overall incidence of GTD is low, but significantly increased 
over the last fourteen years. This can only partially be explained by increased 
maternal age and an increased portion of live births of Asian descent, since their 
part of the total number of deliveries is small. In addition, part of the documented 
increase might also result from improved diagnostic techniques. However, these 
factors do not seem to account for the total observed increase and part of the 
increase therefore remains unexplained. Rates found in HM and choriocarcinoma 
are consistent with rates found in previous population-based studies in Western 
countries. To provide useful information, population-based studies should be performed, 
preferably through a centralized registry to ensure unbiased and non-selected data.
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Abstract
  
Background Currently, hCG follow-up after evacuation of hydatidiform moles is 
essential to identify patients requiring chemotherapeutic treatment for gestational 
trophoblastic neoplasia (GTN). Here we propose a model based on linear regression 
of post-evacuation serum hCG concentrations for the prediction of post-molar GTN.
Methods A total of 113 patients with at least three serum samples from day 7-28 
after evacuation were selected from the Dutch Central Registry for Hydatidiform 
Moles (1994-2009). The slopes of the linear regression lines of the first three log-
transformed serum hCG and free beta hCG values were calculated. Receiver 
operating characteristic (ROC) curves were constructed to calculate Areas Under 
Curve (AUCs).
Results The slope of the hCG regression line showed an AUC of 0.906 (95% CI 
0.845-0.967). GTN could be predicted in 52% of GTN patients at 97.5% specificity 
(cut-off -0,020). 21% of GTN patients could be predicted before diagnosis according 
to the FIGO 2000 criteria. The slope of free beta hCG showed an AUC of 0.844 (95% 
CI 0.752-0.935), showed 69% sensitivity at 97.5% specificity, and 38% of GTN patients 
could be predicted before diagnosis according to the FIGO criteria.
Conclusion The slope of the linear regression line of hCG proved to be a good test to 
discriminate between patients that achieve spontaneous disease remission and 
patients developing GTN. The slope of free beta hCG seems to be a better predictor 
for GTN than the slope of hCG. Although this model needs further validation for 
different assays, it seems a promising way to predict the more aggressive cases of 
GTN.
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Introduction 
Hydatidiform mole (HM) is a non viable form of pregnancy with a cystic appearance 
of chorionic villi, most often in the absence of an embryo. HM occurs in approximately 
1-3 per 1000 pregnancies.1 Following molar evacuation by uterine curettage, remaining 
trophoblastic tissue resolves spontaneously in most cases. However, 15% of all complete 
molar pregnancies (CHM) and 1-5% of partial moles (PHM) develop gestational 
trophoblastic neoplasia (GTN) which is a malignant condition.2 According to the 
criteria of the International Federation of Gynecology and Obstetrics (FIGO), post-
hydatidiform mole trophoblastic neoplasia (GTN) is defined as 1) a plateau in weekly 
serum hCG concentrations for four consecutive measurements, 2) an increase in serum 
hCG levels in three weekly consecutive measurements, 3) persistence of detectable 
hCG levels for more than 6 months after evacuation, and 4) the presence of a 
histologic diagnosis of choriocarcinoma.3
 The pathogenesis of GTN remains to be elucidated; it is unknown why some HM 
patients develop GTN, whereas others achieve spontaneous disease remission 
following HM evacuation. Prognostic markers to predict GTN are lacking. Therefore, 
hCG follow-up after evacuation of HMs currently is essential for all patients to 
identify those requiring chemotherapeutic treatment for GTN. If treated instantly, 
the prognosis of post-molar GTN, including choriocarcinoma, is excellent, with an 
overall survival rate of more than 98%.4 
 Many efforts have been made to predict GTN at an early stage of the disease.5-8 
Although clinical and pathological features have been evaluated for their potential 
in defining a subset of patients at high risk of persistent disease, much of this 
research has focused on serum hCG as a tumour marker.9-11 Previously, our group 
performed several studies showing that post-molar GTN can be predicted using 
ratios from pre- and post-evacuation serum hCG levels, ratios from post-evacuation 
hCG levels, hCG subunit ratios and chromatofocusing of hCG.12-14 Up to date, no 
generally accepted method for prediction of GTN prior to the clinical detection by 
FIGO 2000 criteria, is available. In the present study we propose a model based on 
the slope of the linear regression line of three consecutive serum hCG measurements 
in the first weeks after evacuation for the prediction of GTN.
Methods
Patients
In the Netherlands, patients with gestational trophoblastic disease (GTD) are 
registered at the Dutch Central Registry for Hydatidiform Moles (DCRHM) residing 
at the Radboud University Nijmegen Medical Centre (RUNMC). This voluntary 
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registry serves as an epidemiological database and provides a national hCG assay 
service to gynaecologists. Patients diagnosed with a molar pregnancy and with at 
least three hCG values from day 7 up to day 28 after evacuation were selected from 
the DCRHM from 1994-2009 (n=113). Of these patients, 42 developed GTN whereas 
in 71 patients the hCG levels returned to normal after evacuation.
Immunoassays
All hCG concentrations are measured using an in-house developed radioimmu-
noassay (RIA) based on polyclonal antibody raised in rabbits.15 This assay detects 
intact hCG and free β-subunit: hCG+hCGβ. Free beta hCG was measured using a ra-
dioimmunoassay based on a monoclonal antibody.15 A highly purified hCG beta 
subunit preparation labelled with Iodine-125 was employed as a tracer for both 
assays. The RIAs for hCG+hCGβ and hCGβ were calibrated with the third International 
Standard Preparations for intact hCG and hCG beta subunit, respectively.
Statistics
Serum hCG levels and serum free beta hCG levels were analyzed as a function of 
time. Log transformation was performed on all hCG and free beta hCG values to 
obtain normal distribution of the data. After log-transformation, data in both 
groups were distributed normally (spontaneous normalisation group Kolmogorov–
Smirnov p=0.200; GTN group Shapiro-Wilk p=0.246). The follow-up guidelines 
after evacuation of a molar pregnancy recommend weekly serum hCG measurements 
after evacuation until the hCG is normalised in three consecutive measurements. 
The first hCG measurement should be obtained one week after evacuation. The 
slope of the linear regression line of serum hCG was calculated using the linear least 
squares regression method (y=ax+b, with y representing the logarithm of the hCG 
concentration, x representing the time in days, a representing the slope, and b 
representing the intercept y) of the first three hCG concentrations from day 7 up to 
day 28 after evacuation. An upper limit of 28 days was chosen in order to be able to 
predict GTN earlier than diagnosis using FIGO 2000 criteria. The slopes of the linear 
regression lines of hCG were analyzed using receiver operating characteristic (ROC) 
curves to calculate Areas Under Curve (AUCs) and sensitivity and cut-off values at 95 
and 97.5% specificity for both hCG and free beta hCG. GTN was the only endpoint 
used in the analysis. In addition, the specificity at 100% sensitivity was assessed to 
determine whether GTN could be ruled out. 
 For the patients in which GTN could be predicted at 97.5% specificity, the day of 
the third hCG or free beta hCG measurement was chosen as the day after evacuation 
at which GTN could be predicted. The time interval between the day of evacuation 
and the day GTN could be predicted was compared to the time interval between the 
day of evacuation and the day at which the GTN was diagnosed according to the 
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FIGO 2000 criteria. In addition, the number of chemotherapy courses administered 
(methotrexate (MTX) as well as additional multi-agent chemotherapy) was 
compared between patients that could be predicted and patients that could not be 
predicted as developing GTN by the slope of the linear regression line at 97.5% 
specificity, using the Mann-Whitney Test. P values of less than 0.05 were considered 
statistically significant.
Results
One hundred thirteen patients with a minimum of three hCG values from day 7 up 
to day 28 after evacuation were selected. In the group of patients that showed 
spontaneous disease remission (n=71), 57 patients were diagnosed as having a 
complete HM, 12 patients had a partial HM, and 2 patients were diagnosed as having 
a HM without further specification into complete or partial HM. Of the patients that 
developed GTN (n=42), 26 patients were initially diagnosed with a complete HM, 1 
patient had a partial HM, and 15 patients were diagnosed as having a HM without 
further specification into complete or partial HM. All GTN patients had low-risk 
disease and were initially treated with MTX, except for one patient who was treated 
with a hysterectomy. Seven patients required additional treatment with multi-agent 
chemotherapy.
 Figure 1 illustrates regression curves and the slope of the first three hCG values 
from day 7-28 after evacuation from patients that showed spontaneous disease 
remission and from patients that developed GTN. Using the slopes of hCG (right 
panel), a clearer distinction can be made between patients showing spontaneous 
normalisation of hCG levels and patients developing GTN compared to using the 
regression curves (left panel). In all patients that showed spontaneous disease 
remission, the slope of hCG was negative (range -0.346 to -0.018). In patients that 
developed GTN, 24 patients had a negative slope, whereas 18 patients had a positive 
slope (for n=42 range -0.202 to 0.157). The slope of hCG and free beta hCG for 
patients showing spontaneous disease remission and for those developing GTN, and 
ROC curves for the slope of hCG and free beta hCG are shown in Figure 2. For hCG, 
the AUC was 0.906 (95% CI 0.845-0.967), and the slope of hCG could predict GTN in 
52% of the GTN patients at 97.5% specificity (cut-off value -0,020). At 95% specificity, 
GTN could be predicted in 74% of GTN patients (cut-off value -0.063). For free beta 
hCG, the AUC was 0.844 (95% CI 0.752-0.935). Using the slope of free beta hCG, GTN 
could be predicted in 69% of GTN patients at 97.5% specificity (cut-off value -0,063) 
and in 69% of GTN patients at 95% specificity (cut-off value -0.067). In addition, the 
slope of the linear regression line was used to rule out GTN. Using the slope of hCG, 
100% of GTN was predicted at a cut-off value of -0.205. In 10% of patients that 
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showed spontaneous disease remission the slope was smaller than -0.205 and GTN 
could be ruled out. Using the slope of free beta hCG, only 1% of patients that showed 
spontaneous disease remission could be ruled out from developing GTN (100% 
sensitivity; cut-off-0.310).
Of the patients that could be predicted at 97.5% specificity using the slope of the 
linear regression line, the day GTN could be predicted was compared to the day GTN 
was diagnosed using FIGO criteria. Table 1 shows patients predicted as developing 
GTN according to the slope of the linear regression line and time to diagnosis 
according to FIGO. Using the slope of hCG, 22 patients could be predicted as 
developing GTN. In 9/22 (41%) of these predicted GTN patients, the slope of hCG 
predicted GTN before diagnosis using the conventional FIGO criteria with a median 
Figure 1   Regression curves (a) and the slopes of the linear regression lines of  
the first three hCG values (b) from day 7 up to day 28 after evacuation 
from patients showing spontaneous disease remission (n=71).  
Regression curves (c) and the slope of the first three hCG values  
(d) from day 7 up to day 28 after evacuation from GTN patients (n=42). 
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of 7 days before FIGO diagnosis (range 4-19). This corresponds to 21% (9/42) of all 
GTN patients that could be predicted before diagnosis according to the FIGO criteria. 
Using the slope of free beta hCG, 29 patients could be predicted as developing GTN. 
In 16/29 (55%) of these predicted GTN patients, the slope of free beta hCG predicted 
GTN before the conventional FIGO criteria with a median of 7 days before FIGO 
(range 4-49 days). This corresponds to 38% (16/42) of all GTN patients that could be 
predicted before diagnosis according to the FIGO criteria. 
Figure 2   a. Slope of the linear regression line of hCG and c. of free beta hCG from 
day 7 up to day 28 after evacuation from patients showing spontaneous 
disease remission (n=71) and patients developing GTN (n=42). Thick line 
indicates the optimal cut-off level b. ROC curve for the slope of hCG, 
showing 52% sensitivity at 97.5% specificity and 74% sensitivity at 95% 
specificity d. ROC curve for the slope of free beta hCG, showing 69% 
sensitivity at 97.5% and 95% specificity
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Table 1   Patients predicted as developing GTN according to the slope of the linear 
regression line of hCG and free beta hCG and time to diagnosis according 
to FIGO.
Patient
hCG
(days)
Free beta hCG
(days)
FIGO
(days)
Time gained 
(days)
1 20 20 39 19
2 22 22 30 8
3 26 26 34 8
4 27 27 34 7
5 23 23 30 7
6 28 28 35 7
7 23 23 29 6
8 25 25 31 6
9 18 18 22 4
10 Not predicted 24 73 49
11 Not predicted 19 40 21
12 Not predicted 22 39 17
13 Not predicted 24 31 7
14 Not predicted 26 33 7
15 Not predicted 25 31 6
16 Not predicted 23 27 4
17 20 20 20 0
18 27 27 27 0
19 28 28 28 0
20 27 27 27 0
21 21 21 21 0
22 26 26 26 0
23 25 25 25 0
24 24 24 24 0
25 26 26 26 0
26 28 28 28 0
27 26 26 26 0
28 20 20 20 0
29 27 27 20 -7
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To determine whether patients that could be predicted as developing GTN were the 
patients that had the more aggressive tumours and therefore required more courses 
of chemotherapy, we compared the number of chemotherapy courses administered 
between the patients that could be predicted as developing GTN at 97.5% specificity 
and the patients in whom GTN was not predicted using the slope of the linear 
regression line. The number of chemotherapy courses administered was known for 
all but one of the GTN patients. One patient received an abdominal hysterectomy 
instead of chemotherapy, after which the hCG levels regressed to normal. In the 
group of patients that could be predicted as developing GTN using the slope of hCG 
(n=22), the median number of chemotherapy courses administered was 6.5 (range 
4-20 courses), including four patients requiring multi-agent chemotherapy due to 
MTX resistance. The group of patients in whom GTN was not predicted (n=20) was 
treated with a median number of 5 courses (range 2-16 courses) of chemotherapy, 
including three patients that required multi-agent chemotherapy (Mann Whitney 
p=0.033). In the group of patients that could be predicted as developing GTN using 
the slope of free beta hCG (n=28), the median number of chemotherapy courses 
administered was 6.5 (range 4-20 courses), including six patients requiring multi- 
agent chemotherapy due to MTX resistance. In the group of patients in whom GTN 
was not predicted (n=12) a median number of 4.0 courses (range 2-12 courses) of 
chemotherapy was administered, including three patients that required multi-agent 
chemotherapy (Mann-Whitney p=0.001).
Discussion
The present study aimed at identifying the value of a model based on the slope of 
the linear regression line of serum hCG or free beta hCG concentrations during the 
first weeks after evacuation for the prediction of GTN. Interpretations of the 
ROCAUC are based on the traditional academic point system, where 0.5 to 0.6 
classifies the test as a fail, 0.6 to 0.7 as poor, 0.7 to 0.8 as fair, 0.8 to 0.9 as good, and 
0.9 to 1.0 as excellent.16 With AUCs of 0.906 and 0.844 for hCG and free beta hCG, 
respectively, this model proved to be a good test to discriminate between patients 
that achieve spontaneous disease remission following HM evacuation and patients 
that will develop GTN. We showed that at 97.5% specificity, 52% and 69% of patients 
that will eventually develop GTN could be predicted by the slope of the linear 
regression line of hCG or free beta hCG, respectively. In 21% and 38% of the GTN 
patients, respectively, the slope of hCG and free beta hCG predicted GTN before 
diagnosis using the FIGO criteria. The slope of free beta hCG seems to be a better 
test to predict GTN than the slope of hCG.
 A possible explanation for the  better performance of the slope of free beta hCG 
in predicting GTN might be that as tumours become more malignant, a relatively 
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higher amount of free beta hCG is produced.17-19 Fan et al. concluded that the 
production of free beta hCG increases with the immaturity of the trophoblastic cell, 
and the degree of differentiation of trophoblastic cells may be reflected by the free 
beta hCG to hCG ratio.17 Ozturk et al. showed that beta hCG to hCG ratios increased 
from normal pregnancy to complete HM to choriocarcinoma.18 Harvey et al. showed 
that choriocarcinoma patients and PSTT patients had significantly higher free beta 
hCG concentrations than GTN patients.20 
 Previous studies have also attempted to predict GTN using hCG values. Some 
authors tried to find absolute hCG levels predictive of outcome.10 However, estimating 
an absolute hCG cut-off to predict GTN is highly dependent on the assay used to 
determine the hCG values, and therefore seems unfeasible to apply in a wide setting. 
Other authors have developed normograms for spontaneous regression of serum 
hCG to predict GTN.9;11;21-25 The use of normograms, however, also bears the disadvantage 
that each individual hCG assay requires the construction of its own normogram 
since the cut-off of hCG used for prediction of GTN will vary depending on the assay 
used due to differences in assay specificity and standardization. Our group therefore 
previously attempted to predict GTN using ratios of two hCG values in serum. 
Although serum concentrations of hCGα, hCGβ and hCG+hCGβ concentrations in 
pre-evacuation serum were significantly higher in patients with GTN compared 
with patients with spontaneous regression after evacuation, none of the calculated 
ratios, however, had adequate diagnostic accuracy for the prediction of persistent 
disease.12 The hCG ratios obtained from post-evacuation hCG levels (dividing the 
first available hCG concentration of a specimen taken within the first 2 weeks after 
evacuation by the hCG concentration of a specimen taken in following weeks) 
showed an increasing diagnostic potential.13 Recently, Kim et al. showed that GTN 
could be predicted by the hCG regression rate obtained by dividing the hCG by the 
initial hCG with a sensitivity of 48.0% and specificity of 89.5% (AUC 0.759) in the 
second week after evacuation, although only patients were selected with an initial 
hCG level of more than 100,000 IU/L.26 
 The prediction model presented in the current study is based on three hCG 
measurements, making the slope of the linear regression line more stable compared 
to a model based on two measurements. However, it is clear that the additional hCG 
value needed negatively affects early prediction of GTN. In the present study, in 21% 
(9/42) of GTN patients using the hCG model, and in 38% (16/42) of GTN patients 
using the free beta hCG model, GTN was predicted before diagnosis using the FIGO 
criteria. Unfortunately, since the protocol for follow-up after evacuation recommends 
weekly hCG measurement, our database did not contain sufficient hCG measurements 
for each patient to determine the time that can be gained maximally in predicting 
GTN using the slope of the linear regression line. Therefore, this model would have 
to be prospectively applied on more frequently obtained hCG measurements in 
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serum. Prediction of GTN at an earlier stage so that treatment can be started earlier, 
is particularly important for patients lost to follow-up by the time GTN would be 
diagnosed with the FIGO criteria, as is often the case in developing countries. In 
addition, early prediction of GTN allows start of treatment at a less advanced stage 
of the disease and also enables earlier permission for a renewed pregnancy, which is 
usually very important for these patients.
 In total, 83 patients were diagnosed with a complete HM, 13 patients had a 
partial HM, and 17 patients were diagnosed as having a HM without further 
specification into complete or partial HM. Although we did not apply the slope of 
hCG on the separate histological groups due to the small number of patients, Smith 
et al. previously showed that no statistically significant differences were found 
when the coefficients of regression of hCG in patients with complete HM, partial 
HM and non-molar abortion were compared.27 Kim et al. also showed that the hCG 
regression rate showed no significant difference between complete and partial 
moles in the spontaneous regression group.26 
 In the group of patients that could be predicted as developing GTN, the median 
number of chemotherapy courses administered was significantly higher compared to 
the group of patients in whom GTN was not predicted. It seems within reason that the 
patients with the most aggressive tumours show a less strong decline or even increase 
in their regression curve (with a corresponding less negative or even positive slope) and 
therefore could be predicted using the slope of the regression line, and that these are 
also the patients that required more chemotherapy courses to obtain remission. 
 Strengths of the study are that the proposed prediction model is not based on 
absolute hCG values but on the steepness of the regression curve. This may enable 
application of this model on multiple (commercial) hCG assays, although this needs 
to be confirmed in other studies. In addition, the prediction model is based on three 
hCG measurements, providing a reliable reflection of the course of the hCG level. A 
limitation is that retrospective hCG data were used that were supplied from clinical 
practice. More frequent blood sampling is needed after evacuation to determine the 
time that can be gained maximally in predicting GTN.
 In conclusion, the slope of the linear regression line proved to be an accurate test 
to discriminate between patients that achieve spontaneous disease remission and 
patients that will develop GTN. The slope of free beta hCG seems to be a better test to 
predict GTN than the slope of hCG. Sixty-nine percent of patients that will eventually 
develop GTN could be predicted within 28 days after evacuation at 97.5% specificity by 
the slope of free beta hCG. In 38% of GTN patients the slope of free beta hCG predicted 
GTN before diagnosis using the FIGO criteria. In addition, patients that could be 
predicted as developing GTN required more courses of chemotherapy to obtain 
remission. Although this model needs further validation on different assays, it seems 
a promising way to predict the more aggressive cases of GTN.
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Relapse rates after two versus three 
consolidation courses of methotrexate 
in the treatment of low-risk gestational 
trophoblastic neoplasia
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Abstract 
Background Methotrexate (MTX) alternating with folinic acid is a commonly used 
treatment regimen for low-risk gestational trophoblastic neoplasia (GTN). In the 
Netherlands, two courses of MTX are administered after Normalisation of serum 
human chorionic gonadotrophin (hCG) levels (consolidation courses), whereas in 
the United Kingdom, three consolidation courses are given. In a retrospective setting 
we compared relapse rates of women completing MTX therapy for low-risk GTN in 
the Netherlands and the UK.
Methods From 1980 to 2008, 351 patients were collected from the Dutch Central 
Registry for Hydatidiform Moles and records from the Dutch Working Party on 
Trophoblastic Disease. From the Charing Cross Hospital Trophoblast Disease Centre 
(London), 600 low-risk GTN patients were identified from 1992 to 2008. 
Results In 4.0% of patients relapse occurred after MTX treatment with three 
consolidation courses, whereas 8.3% of patients relapsed after MTX treatment with 
two consolidation courses (p=0.006). Although patients from the Netherlands had 
a higher level of hCG (p<0.001) and more patients had metastases before the start 
of treatment (p=0.012), the number of courses of MTX to achieve a normal hCG did 
not differ significantly between patients from the Netherlands and the UK (p=0.375). 
Conclusion Relapse rates were higher in patients treated with two consolidation 
courses of MTX. Although other factors might have influenced the observed 
difference in relapse rates, three courses of consolidation chemotherapy may be 
preferable to two in the treatment of low-risk GTN in order to decrease the risk of 
disease relapse. A prospective randomized study would be required to confirm these 
findings.
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Introduction
 
A hydatidiform mole (HM) is an abnormal pregnancy with excessive proliferation of 
placental villi but severely stunted or absent embryonic development. This condition 
affects one to three per 1000 pregnancies in western countries 1;2 and can be 
classified into complete (CHM) or partial HM (PHM).3 Management of both CHM 
and PHM is similar: surgical evacuation followed by regular measurement of serum 
human chorionic gonadotropin (hCG) until the levels have returned to normal. 
Normalisation occurs in the 80-90% of women. However, in the presence of three 
consecutive static or rising weekly hCG levels during follow-up, patients are defined 
as having gestational trophoblastic neoplasia (GTN). In the Netherlands, an 
additional criterion was added to this definition in 1993. At least one of the values 
should exceed the 95th percentile of the hCG regression corridor of uneventful 
decline as constructed by Yedema et al.4 
  GTN is an indication for chemotherapeutic treatment. Depending on the stage 
of the disease, patients are treated with either single-agent therapy for low-risk 
disease, or multi-agent therapy for high-risk disease.5 In the Netherlands and the UK, 
low-risk patients receive intramuscular methotrexate (MTX) (1 mg/kg or 50 mg total, 
respectively) on days 1, 3, 5 and 7 alternating with oral folinic acid (FA) 15 mg on days 
2, 4, 6, and 8, repeated every two weeks.6-8 Treatment continues until the hCG level 
is normal and then for a further consolidation period. The number of courses of MTX 
administered after normalisation of serum hCG levels in order to eradicate the 
remaining tumour cells differs between the Netherlands and the UK. In the 
Netherlands, two consolidation courses are given, whereas in the UK, MTX treatment 
is consolidated over three further courses after normalisation of hCG levels.4;8;9 
Evidence exists that relapse rates after MTX treatment diverge between the 
Netherlands and the UK, although definitions of relapse differed between these 
studies.10;11 Disease relapse requires treatment with multi-agent chemotherapy, 
which, in contrast to MTX, is associated with an increased incidence of secondary 
malignancies and increases the risk of an early menopause.12-14 Therefore an 
additional course of MTX would be preferred if this decreases the chance of 
developing relapsed disease. In the present study we have retrospectively compared 
the percentage of disease relapse in a large cohort of women with low-risk GTN, 
treated with either two (the Netherlands) or three (UK) consolidation courses of MTX. 
Methods
In the Netherlands, patients with gestational trophoblastic disease (GTD) are 
registered at the Dutch Central Registry for Hydatidiform Moles (DCRHM) residing 
at the Radboud University Nijmegen Medical Centre (RUNMC). This voluntary 
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registry serves as an epidemiological database and provides a national hCG assay 
service to gynaecologists. Between 1977 and 2010, 3983 patients were registered at 
the DCRHM. Patients are treated in different referral hospitals with the Dutch 
Working Party on Trophoblastic Disease having a coordinative and advisory function. 
Data on patients with low-risk GTN were collected retrospectively from 1980 to 
2008 from the DCRHM and from records of the meetings of the Dutch Working 
Party. According to the Dutch guideline for classification of GTN, low-risk disease is 
defined as GTN with as antecedent pregnancy a mole or abortion, no metastases or 
metastases restricted to vagina or lungs, no previous chemotherapy administered, 
and an interval of ≤ 12 months between the end of pregnancy and beginning of 
treatment. Patients who developed MTX resistant disease and therefore required 
additional treatment with multi-agent chemotherapy were not included. A total 
number of 401 low-risk GTN patients with normal hCG values after MTX treatment 
were selected. At the assay service of the DCRHM, all hCG concentrations are 
measured using an in-house  developed radioimmunoassay (RIA) based on polyclonal 
antibody raised in rabbits. This assay detects intact hCG and free β-subunit: 
hCG+hCGβ. Using this assay, serum hCG concentrations of less than 2 ng/ml are 
considered normal. For patients  whose serum hCG was measured in another 
hospital on a different assay, the reference values provided by the manufacturer of 
the assay were considered normal. After the first normalized hCG level the guidelines 
from the Dutch Society for Obstetrics and Gynaecology recommend two additional 
courses of MTX.6 Patients who received less than two consolidation courses of MTX 
(n=19) or more than two consolidation courses of MTX (n=31) were excluded from 
further analysis. The remaining 351 patients were included in the study. 
 In the United Kingdom, all patients with GTD are registered with one of three 
centres for hCG monitoring and, if necessary, referred to one of the two centres for 
treatment (Charing Cross Hospital Trophoblast Disease Centre, London or Sheffield 
Trophoblastic Disease Centre, Sheffield). From the Charing Cross Hospital 
Trophoblast Disease Centre, 610 patients were identified who were successfully 
treated with MTX for low-risk GTN from 1992 to 2008. Before 1992, patients were 
stratified in three prognostic categories according to the Charing Cross scoring 
system, namely high (score>9), medium (score 6-9) or low risk (score 0-5). After 
1992, patients were classified as either low-risk (score 0-8 on the Charing Cross 
scoring system; similar to score 0-6 on the revised prognostic scoring system of the 
International Federation of Gynecology and Obstetrics (FIGO)) or high risk (score >8, 
corresponding to a FIGO score of >6). In order to compare the same risk categories 
between the Netherlands and the UK, patients treated at the Charing Cross Hospital 
were included from 1992 onwards. Patients whose treatment protocol was changed 
due to MTX-resistance or toxicity were not included. According to the guidelines 
from the Royal College of Obstetricians and Gynaecologists (RCOG), three 
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consolidation courses of MTX should be administered after normal hCG levels are 
obtained. At the Charing Cross Hospital, hCG detection and monitoring is done with 
a non-commercial, one-site, in-house, competitive hCG radioimmunoassay that 
uses a rabbit polyclonal antibody. Serum hCG concentrations of less than 5 IU/L are 
considered normal. Patients who received less than a total of four courses of 
methotrexate (n=10) were also excluded from further analysis. Patients with the 
histology of a placental site trophoblastic tumour were excluded from the study. 
The remaining 600 patients were included in the study.
 Indications for chemotherapy following a molar pregnancy are similar between 
the Netherlands and the UK. Indications for chemotherapy in the Netherlands 
include: a plateaued or rising hCG concentration in three consecutive weekly 
measurements after evacuation, or a histological diagnosis of choriocarcinoma. In 
addition, in the UK chemotherapy is started for a serum hCG concentration of more 
than 20,000 IU/L at 4 weeks or more after evacuation, lung or vaginal metastases 
more than 2 cm in diameter, or heavy vaginal bleeding, and until recently for a 
persistently raised but falling hCG at 6 months after evacuation.
 Patient characteristics were compared between patients from the Netherlands 
and from the UK on maternal age, tumour histology, hCG level before the start of 
MTX, presence of lung metastases and metastases elsewhere. The hCG values 
before start of MTX treatment were categorized according to the FIGO 2000 
prognostic scoring system into <103, 103-104, 104-105, and >105 IU/L. In addition, the 
number of courses of MTX required to achieve normal hCG levels were noted.
 Disease relapse was defined as a rise in serum hCG values after termination of 
the consolidation courses of MTX, in the absence of a new pregnancy. This 
corresponds to six weeks after normalisation of serum hCG for the patients who 
received treatment in the UK, and four weeks after normalisation for patient treated 
in the Netherlands. Increasing serum hCG levels during consolidation therapy were 
not considered as relapsed disease. Statistical analyses were performed using SPSS 
16.0 software. Differences in disease relapse between two and three consolidation 
courses of MTX were determined using Pearson Chi-square tests. Differences in 
number of courses to normalisation were compared using Mann-Whitney U Test. 
Statistical differences were considered significant at p<0.05.
Results
 
From 1980 to 2008, 351 women with low-risk GTN with normalisation of hCG levels 
after MTX treatment were collected from records from the DCRHM and the Dutch 
Working Party on Trophoblastic Disease. From the Charing Cross Hospital database, 
600 low-risk patients successfully treated with MTX were identified from 1992 to 
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2008. Patient characteristics of these patients before the start of MTX treatment 
are shown in Table 1. Mean maternal age at diagnosis was 30.3 and 31.1 years in 
patients from both the Netherlands and from the UK, respectively (p=0.113). In the 
majority of patients from the Netherlands and from The UK, the tumour histology 
showed a molar pregnancy (95.8% and 94.6%, respectively). The level of serum hCG 
before start of MTX treatment was not the same between patients from The 
Netherlands and from The UK (p<0.001). More patients with an hCG level of 
>100,000 IU/L were found in the Netherlands compared to the UK (7.4% versus 2.2%, 
respectively). The percentage of patients with metastases prior to MTX chemo - 
therapy was 9.9% in the Netherlands and 6.0% in The United Kingdom (p=0.012).
Table 1   Patient characteristics of low-risk GTN patients from the Netherlands and 
the UK before the start of MTX treatment.
The Netherlands
N=351
United Kingdom
N=600
Significance
P
Age at diagnosis (y) (N=351) (N=600) 0.113#
          Mean (range) 30.3 (15-53) 31.1 (15-56)
Histology (N=351) (N=600) <0.001*
          Complete HM 161  (45.9%) 491  (81.8%)
          Partial HM 54    (15.4%) 50    (8.3%)
          Unspecified mole‡ 121  (34.5%) 27    (4.5%)
          Choriocarcinoma 9       (2.6%) 18    (3.0%)
          Non-molar abortion 6       (1.7%) 14    (2.3%)
Serum hCG before start MTX (IU/L) (N=324) (N=600) <0.001*
          <1000 89    (27.5%) 184  (30.7%)
          1001-10,000 119  (36.7%) 193  (32.2%)
          10,001-100,000 92    (28.4%) 210  (34.9%) 
          100,001-1,000,000 24    (7.4%) 13    (2.2%)
Metastases (N=304) (N=600)^ 0.012*
          None 274  (90.1%) 565 (94.0%)
          Lungs 28    (9.2%) 27   (4.5%)
          Elsewhere (vagina) 2      (0.7%) 9     (1.5%)
‡ Pathologically confirmed mole, not further specified into complete or partial HM
^ One patient had metastases in both lungs and vagina
* Chi-square
# T-test
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 The number of MTX courses to achieve a normal hCG level was compared 
between patients from the Netherlands (N=332) and the United Kingdom (N=464). 
In the UK, 3.94 courses were given on average to reach normal hCG levels (median 4 
courses, range 1-12), compared to an average of 4.25 MTX courses to normalisation 
(median 4, range 1-18) in the Netherlands (Mann Whitney p=0.375). Table 2 shows 
relapse rates after two and three consolidation courses of MTX in the Netherlands 
and the United Kingdom, respectively. From the patients who were treated with two 
consolidation courses of MTX, 8.3% (29/351) developed disease relapse, compared to 
4.0% (24/600) of the patients who were treated with three consolidation courses of 
MTX (p=0.006). In patients with non-metastatic disease, relapse rates were 8.0% 
(22/274) and 4.1% (23/564) in the Netherlands and the UK, respectively. In 13.3% 
(4/30) of patients with metastatic disease in the Netherlands, disease relapse 
occurred, compared to 2.9% (1/35) of patients with metastatic disease in the UK.
Discussion 
The present study showed that 4.0% of low-risk GTN patients relapsed after MTX 
treatment with three consolidation courses after normalisation of hCG levels, 
whereas 8.3% of patients relapsed after MTX treatment with two consolidation 
courses after hCG normalisation. Several previous studies have examined relapse 
rates after MTX treatment for low-risk GTN, although some have combined patients 
normalizing on MTX with patients who had progressive disease on MTX and 
therefore had to switch to more aggressive chemotherapy.10;11;15-19 Among 20 patients 
treated with MTX for low-risk GTN, including patients who showed MTX resistance, 
Matsui et al. found that one patient developed relapsed disease (5%).19 For 
non-metastatic cases, one course of MTX consolidation treatment was given, 
whereas metastatic cases received two additional courses after normalisation of 
the hCG levels. Powles et al. found that 35 of 1397 (2%) low-risk patients relapsed. 
Table 2   Relapse rates in patients treated with two versus three consolidation 
courses of MTX for low-risk GTN.
Two MTX 
consolidation 
courses (n=351)
Three MTX 
consolidation 
courses (n=600)
Significance
P
Disease relapse 29     (8.3%) 24    (4.0%) 0.006*
No relapse 322   (91.7%) 576  (96.0%)
* Chi-square
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Although these patients initially started with low-risk treatment, eight of the 
relapsed patients became resistant to MTX and changed to more intensive 
chemotherapy.20 Ngan et al. found a relapse rate of 4.6% in 153 low-risk GTN patients 
treated with single-agent chemotherapy with MTX or etoposide. In this study, 
relapse was diagnosed if the serum hCG rose one month or later after cessation of 
chemotherapy.16Between 1999 and 2006, only 1.8% of the low-risk GTN patients 
who responded to MTX had recurrent disease after hCG normalisation in the French 
Trophoblastic Disease Reference Centre.18 
 Few studies have illustrated the importance of consolidation therapy. Yang et al. 
identified less than two courses of consolidation chemotherapy as a risk factor for 
relapsed disease.21 In their study, the relapse rate of low-risk patients was 2.9%, 
although recurrence was defined as an increase of serum hCG values 3 months after 
complete remission. Mutch et al. found that no consolidation chemotherapy after 
the first normalized hCG level was related to development of relapsed disease.15 Sun 
et al. reported a 2.4% recurrence rate in low-risk choriocarcinoma patients, and 
analyzed the factors associated with recurrence. Especially interesting was their 
finding that recurrence rates among patients without and with one course of 
consolidation chemotherapy were 6.1% (3/49) and 9.8% (6/61), respectively, while in 
2, 3 and >3 courses of consolidation chemotherapy recurrence rates were 1.4% (1/70), 
3.9% (2/51) and 3.1% (5/163), respectively.17 However, this difference might be a 
chance finding because of the very small number of patients who relapsed. In the 
same study, a relapse rate of 2.5% was found in patients with non-metastatic disease 
who received one cycle of consolidation chemotherapy, compared to a 8.0% and 
4.1% relapse rate in patients with non-metastatic disease in the Netherlands and the 
UK, respectively. However, patients with non-metastatic disease in the study by 
Mutch et al. were treated with single agent chemotherapy in the form of either 
methotrexate, methotrexate with folinic acid rescue, or actinomycin D.15
 Relapse rates in low-risk GTN patients in the Netherlands and in the UK have 
been described previously. Kerkmeijer et al. found a relapse rate of 8.1% in 74 low-risk 
GTN patients treated with MTX/FA in the Netherlands.10 McNeish et al. studied 324 
low-risk GTN patients treated with MTX/FA in the UK and found a relapse rate of 
3.4%.11 However, definitions of relapse differed between these studies. McNeish et 
al. classified patients as having relapsed disease if the serum hCG value started to 
rise after completing the consolidation courses of MTX, whereas Kerkmeijer et al. 
also classified a raising hCG during consolidation therapy as relapsed disease. In 
order to compare relapse rates, the same definition of relapse should be applied to 
both patient groups, as performed in the present study.
 Other factors than the number of consolidation courses might have influenced 
the difference in relapse rates found in the present study. First, the extra criterion in 
the definition of GTN added in the Netherlands in 1993 of one hCG value exceeding 
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the p95 of the normal regression curve, in addition to a plateau or rise in hCG serum 
concentrations in three subsequent weekly measurements, might have influenced 
the composition of the group of patients in the Netherlands, thereby possibly 
increasing the observed relapse rate. In addition, the broader indications for the 
start of chemotherapy in the UK (persistently raised but falling hCG at 6 months 
after evacuation, a serum hCG concentration of more than 20,000 IU/L at 4 weeks 
or more after evacuation, lung or vaginal metastases more than 2 cm in diameter, or 
heavy vaginal bleeding) might have contributed to the difference in the observed 
relapse rates. 
 Secondly, the level of hCG before the start of MTX treatment was higher in 
patients from the Netherlands compared to patients from the UK. More patients 
treated in the Netherlands had an hCG level higher than 100,000 IU/L. Since the 
response to treatment is known to be influenced by the burden of tumour as 
reflected by the level of hCG, 22;23  this discrepancy might contribute to the higher 
relapse rate in the Netherlands patients. However, different hCG assays were used 
in the Netherlands and in the UK to measure the hCG levels, which might have 
contributed to the observed difference in pre-treatment hCG levels. 
 Finally, the percentage of patients with metastases in the lungs or the vagina 
differed between the Netherlands and the UK. Patients from the Netherlands more 
often had metastatic disease before the start of MTX treatment. However, although 
patients from the Netherlands had a higher serum level of hCG and more patients 
had pulmonary metastases before the start of treatment, no significant difference 
was observed in the number of courses of MTX required to achieve normal hCG 
levels. 
 Other potential limitations of our study are that this is a retrospective analysis 
in which different scoring systems were employed in defining low-risk disease. Thus, 
unlike the FIGO 2000 scoring system, the Dutch guideline does not include scorings 
for age, pre-treatment serum hCG concentration, the number of metastases or 
largest tumour size.6;22 Nevertheless, strengths of our study include its size and to 
the best of our knowledge, this is the first study in which relapse rates following two 
or three consolidation courses of MTX have been investigated.
 In conclusion, the data from this large retrospective analysis showed that 
relapse rates were higher after completing treatment with two consolidation 
courses of methotrexate. Although other factors might have influenced the 
difference in relapse rates found in this study, three courses of consolidation 
chemotherapy may be preferable to two in the treatment of low-risk GTN in order to 
decrease the risk of development of disease relapse. A prospective randomized study 
would be required to confirm these findings. 
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Abstract 
Background We described fatal cases of gestational trophoblastic neoplasia (GTN) 
over four decades in the Netherlands and evaluated whether treatment was given 
according to the protocol and revealed possible implications for future management.
Methods Records from the Dutch Central Registry for Hydatidiform Moles and the 
Working Party on Trophoblastic Disease were used to identify fatal cases of GTN 
from 1971 to 2011. Main outcome measures were disease extent, risk classification, 
treatment regimens and cause of death.
Results Twenty-six patients died from GTN. In five cases GTN developed after a 
hydatidiform mole and in 19 cases following term pregnancy. Half the number of 
patients died between 1971-1980 when patients were not yet classified as having 
low- or high-risk disease and were thus not yet treated accordingly. A major decline 
in the number of deaths was seen after the first decade, with a further decrease 
from 1981-2011. Early death occurred in nine patients. In four of these patients, death 
was treatment related. Patients that died more than four weeks after start of 
treatment mostly died from metastatic tumour (n=14).
Conclusion The yearly number of patients that died from GTN decreased considerably 
over the last four decades. Appropriate risk classification is essential to start optimal 
initial therapy and to prevent therapy resistance. Patients with post-term choriocar-
cinoma represented a large proportion of the deceased patients and we propose 
that these patients are considered as having high-risk disease.
Fatal cases of GTN over four decades in the Netherlands | 71
5
Introduction
Gestational trophoblastic disease (GTD) is a condition in which there is abnormal 
proliferation of placental trophoblastic tissue. It encompasses the benign hydatidiform 
moles (HMs) and gestational trophoblastic neoplasia (GTN) including invasive mole, 
choriocarcinoma, placental site trophoblastic tumours (PSTT), and epithelioid tropho- 
 blastic tumour (ETT). HMs are premalignant non-viable pregnancies that develop 
because of a complication in fertilization. They may develop into post-molar GTN 
(also known as persistent trophoblastic disease) which requires chemotherapeutic 
treatment. However, GTN can occur after any kind of gestation.
 Patients with GTN are classified as having a high or low risk of developing 
resistance to treatment with single-agent chemotherapy. During the years, a number of 
different classification systems were applied that resulted in the current FIGO 2000 
staging system.1 Low-risk disease is treated with single-agent methotrexate (MTX) 
or actinomycin D chemotherapy, whereas high-risk disease is treated with multi- 
agent chemotherapy. The most widely accepted initial treatment for high-risk 
trophoblastic tumour is EMA/CO (etoposide, MTX and actinomycin D, alternating 
with cyclophosphamide and vincristine).
 Prognosis of GTN improved greatly over the past decades. In the 1950s, when 
MTX was introduced as a treatment for GTN, choriocarcinoma had a cure rate of 
approximately 25%.2,3 Nowadays, patients still die from high-risk disease with 
survival rates of 87-91% after treatment with EMA/CO and adjuvant cisplatin-based 
chemotherapy, surgery and radiotherapy.4-7 For low-risk disease, survival rates 
approach 100%.8-10 Literature is limited on cases that fatally failed on treatment.11-14 
Reasons for unsuccessful treatment are late presentation and diagnosis, and drug 
resistance.15,16 The present study reviews all patients who died from GTN over the 
last four decades in the Netherlands and aims to evaluate whether treatment was 
given according to the protocol or guideline at the time of diagnosis and to reveal 
possible implications for future management. 
Methods
Patients
In the Netherlands, patients with GTD, and even GTN are treated in various referral 
hospitals. The Dutch Working Party on Trophoblastic Disease, founded in 1971, has a 
registering and advisory function.16 Since its founding, 788 patients were discussed 
in the meetings of the Working Party. In 1977, the Dutch Central Registry for 
Hydatidiform Moles (DCRHM) was established at the Radboud University Nijmegen 
Medical Centre (RUNMC), which currently contains 4190 records of patients with 
GTD. Data from 34 patients with GTN who died from this disease were collected 
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retrospectively from 1971 to 2011 from the DCRHM and the database of the Working 
Party. After evaluation, eight patients were excluded because of diagnosis of non-
gestational choriocarcinoma, based on suspicion of the clinicians.
 For each patient, data were collected on demographics, disease extent, treatment 
regimens and cause of death. Patients were categorized as early death (within four 
weeks after the start of treatment before adequate chemotherapy could be given) 
or late death (more than four weeks after the start of treatment). The risk 
classification as stated at the time of diagnosis was registered. In addition, patients 
were classified retrospectively using the current Dutch classification system introduced 
in 1983.17 This system defines high-risk disease by the presence of one or more of the 
following features: insufficient response to single-agent chemotherapy; metastasis 
in more than one organ; metastasis in liver, spleen, kidneys, gastro-intestinal tract, 
bones or brain; antecedent term pregnancy; and an interval of more than 12 months 
between the end of the antecedent pregnancy and the start of treatment. Absence 
of all of these features is defined as low-risk disease. Finally, for each patient we 
evaluated whether treatment was given according to the protocol or guideline at 
the time of diagnosis and if not, why treatment deviated from these protocols.
Protocols for the management of GTN
Until 1977, MTX was given to all patients and if resistance occurred, either actinomycin D 
or multi-agent chemotherapy as second line treatment was used.2,18 From 1977 
onwards patients were gradually classified into low-risk or high-risk disease.19
 Treatment for low-risk disease always consisted of MTX with folinic acid rescue, 
although before 1982 different routes of administration and schedules were applied. 
From 1980 onwards, high-risk disease was treated with multi-agent chemotherapy. 
Various chemotherapy regimens were used in the treatment of high-risk GTN. Until 
1982 most patients were treated with CHAMOCA (cyclophosphamide, hydroxyurea, 
actinomycin D, MTX, vincristine, adriamycin), VAC (vincristine, adriamycin, cyclo-
phosphamide) or PLE(M)CA (cisplatin, etoposide, (MTX), cyclophosphamide, 
adriamycin).16,20 Because of high toxicity of CHAMOCA, a platinum containing 
combination chemotherapy schedule (EMACP: etoposide, MTX, cyclophosphamide, 
actinomycin D and cisplatin) was introduced by the Working Party in 1982, aiming to 
create a schedule that could be repeated frequently with a short interval between 
two courses, causing less myelosuppression and containing the new agents 
etoposide and cisplatin. For similar reasons, the EMA/CO regimen was developed in 
the UK. In 1989, EMA/CO was introduced in the Netherlands because of seemingly 
less toxicity compared to cisplatin containing EMACP, and both regimens were used 
simultaneously.21,22 
 If relapse or resistance to multi-agent chemotherapy regimens occurred, a wide 
variety of salvage chemotherapy was given. Since 2004, platinum containing EMA/
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EP therapy (etoposide, MTX and actinomycin D, alternating with etoposide and 
cisplatin) is recommended as salvage chemotherapy after failure of EMA/CO.17,23 
Beside chemotherapy, hysterectomy could be considered in patients with tumour 
confined to the uterus who did not wish to preserve fertility, as salvage therapy and 
in patients with life-threatening haemorrhage. Also, metastasectomy was used in 
some cases as salvage treatment.17 Radiotherapy was used for lung and brain 
metastasis until 1986. Surgery for brain metastases at an early stage combined with 
multi-agent chemotherapy is the currently recommended treatment of choice. 
(Stereotactic) radiotherapy might still be used when the lesions do not respond to 
chemotherapy and cannot be removed neurosurgical. 17
Results
Twenty-six patients died from GTN. Patient characteristics are presented in Table 1. 
The median age of women at the time of diagnosis was 30·5 years. In 21 patients 
histology showed a choriocarcinoma, whereas in five patients a histological 
diagnosis of a hydatidiform mole was made. Five patients developed GTN from 
antecedent HM and 19 patients developed GTN from an antecedent term pregnancy. 
In the case of two patients it was unclear whether the index pregnancy was a HM or 
previous term pregnancy. Seven patients were diagnosed with GTN within four 
months from the index pregnancy, ten patients had an interval from the index 
pregnancy of more than 12 months. Nineteen patients had an hCG level over 10,000 
IU/L before start of treatment, of which eleven patients had hCG levels of more than 
100,000 IU/L. Six patients had no evidence of metastatic disease at presentation. 
Twelve out of 20 patients with metastatic disease at presentation, had metastases 
in more than one organ. Two patients presented with metastases in the gastro-in-
testinal tract, four with brain metastases and three with liver metastases.  
 Figure 1 shows the number of fatal cases of GTN from 1971 to 2011 as well as 
changes in the Dutch protocols and guidelines of management of GTN during this 
period. Thirteen patients died during the first decade, before patients were classified 
into low- or high-risk disease and were treated accordingly. A major decline was seen 
after the first decade, with a further  decrease between 1981-2011.
 Figure 2 shows the causes of death of patients who died either within four 
weeks or after four weeks following the start of treatment. Early death occurred in 
nine of the 26 patients. In four of these patients, death was treatment related. The 
cause of early death of six patients was fatal tumour bleeding, related to treatment 
in one of them (haemorrhage from the lungs after MTX) and unrelated to treatment 
in five patients (uterus, brain and gastro-intestinal bleeding), since tumour bleeding 
occurred before the start of chemotherapy. Two early deaths resulted from sepsis as 
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Table 1   Patient characteristics.
Number of 
patients 
(N=26)
Patient 
numbers
Age (years) 
Median (range) 30.5 (23-55)
Parity 
Median (range) 2 (0-5)
Histology
Choriocarcinoma 21 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 
14, 15, 16, 19, 20, 21, 22, 23, 26
HM 5 5, 17, 18, 24, 25
Index pregnancy
HM 5 5, 17, 18, 24, 25
Term 19 1, 2, 3, 4, 7, 8, 9, 11, 12, 13, 14, 15, 
16, 19, 20, 21, 22, 23, 26
HM or term 2 6,10
Interval from index pregnancy (months)
<4 7 5, 8, 18, 20, 22, 23, 24 
4-6 5 1, 7, 12, 16, 21
7-12 3 15, 19, 26
>12 10 2, 3, 4, 6, 9, 10, 11, 13, 14, 25
Unknown 1 17
Pre-treatment hCG (IU/L)
<1000   0
1000-10,000 4 5, 19, 20, 21
10,000-100,000 8 2, 4, 11, 13, 14, 16, 24, 26
>100,000 11 3, 6, 7, 8, 10, 12, 15, 18, 22, 23, 25
Unknown 3 1, 9, 17
Metastasis site at presentation*
None 6 1, 10, 13, 18, 21, 26
Lung 20 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 15, 
16, 17, 19, 20, 22, 23, 24, 25
Vaginal 3 2, 6, 25
Brain 4 3, 4, 12, 19
Liver 3 11, 15, 20
Spleen/kidney 1 9
Gastro-intestinal 2 9, 11
*Some patients had metastatic spread to several sites
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Figure 1   Fatal cases of GTN in the Netherlands from 1971-2011 (n=26). Major 
changes in the Dutch protocols for management of GTN are indicated.
Figure 2   Causes of death of patients who died within four weeks after start 
of treatment and of patients who died more than four weeks after the 
start of treatment.
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a complication of chemotherapy, one patient died from tumourogenic pulmonary 
embolism shortly after initiation of chemotherapy. The chemotherapy that was 
given shortly before early treatment related death was MTX (in one patient who 
died from lung haemorrhage and in one patient who died from sepsis) and EMACP 
(in one patient who died from sepsis, and in one patient with massive pulmonary 
obstruction due to carcinoma tissue plugs). The patients who died from haemorrhage 
from the lungs was not ventilated prior to the start of bleeding. Between the first 
two decades and the last two decades the relative number of early deaths was 
rather comparable (six out of 19 patients from 1971-1990 and two out of seven 
patients from 1991-2011).
 Patients that died more than four weeks after start of treatment mostly died 
from metastatic tumour (14 out of 17). All these patients had treatment resistance to 
or disease relapse after at least three different chemotherapy regimens (multi-agent 
resistant disease). Ten patients died from fatal tumour bleeding, which included 
haemorrhage from brain metastasis in eight patients. The patient who died from 
haemorrhage from the lungs was not ventilated prior to the start of bleeding. One 
patient died of sepsis, caused by peritonitis after tumour growth through the bowel 
wall. The remaining three patients died at home after cessation of all therapy, thus 
causing uncertainty about the eventual cause of death. Treatment related death in 
patients that died late was due to sepsis from leucopoenia from EMA/CO chemo - 
therapy in one patient, and severe leucopoenia from EP salvage therapy (for multi- 
agent resistant disease) in the other patient. One patient withdrew from therapy 
6 weeks after diagnosis and died abroad.
 Haemorrhage from brain metastasis was the eventual cause of death in ten out 
of the 26 deceased patients. Three patients had brain metastasis at presentation, in 
seven patients brain metastasis developed during treatment. Nine of these patients 
died in the first two decades of the study period, whereas only one patient died from 
brain metastasis in the last two decades of the study period. 
 Table 2 demonstrates risk classification and first treatment. Twelve out of 17 
patients who were initially treated with MTX had high-risk disease according to the 
current Dutch risk classification. In retrospect, risk classification at time of diagnosis 
of nine of these patients was inconsistent with the revised risk classification. Six of 
the nine patients that would now be classified as high-risk were initially treated with 
MTX since they were diagnosed before 1978, when risk classification was not yet 
widely available (patients 2, 3, 4, 7, 8 and 10). The other three patients were classified 
as low-risk at time of diagnosis of GTN and would now be classified as high-risk 
(patients 13, 21 and 26). Risk classification was difficult for two of these patients 
because at the time of diagnosis it was uncertain whether an abortion or term 
pregnancy was the index pregnancy. In another patient, a choriocarcinoma after a 
term pregnancy was diagnosed, without metastases. According to the guidelines at 
Fatal cases of GTN over four decades in the Netherlands | 77
5
Table 2   Risk classification and first treatment in patients deceased from GTN. 
Patients with post-term GTN are marked^
Patient 
number
Year of 
diagnosis
Risk 
classification† 
Revised
risk classification‡
First treatment 
1^ 1970 Not available Low-risk MTX 
2^ 1972 Not available High-risk MTX 
3^ 1974 Not available High-risk MTX 
4^ 1974 Not available High-risk MTX 
5 1975 Not available Low-risk MTX
6 1975 High-risk** High-risk Multi-agent chemotherapy***
7^ 1976 Not available High-risk MTX 
8^ 1976 Not available High-risk MTX 
9^ 1977 High-risk High-risk MTX / actinomycin D
10 1977 Not available High-risk Hysterectomy / MTX 
11^ 1978 High-risk High-risk MTX 
12^ 1980 High-risk High-risk CHAMOCA 
13^ 1980 Low-risk High-risk MTX 
14^ 1980 High-risk High-risk MTX 
15^ 1984 High-risk High-risk EMACP 
16^ 1985 High-risk High-risk EMACP 
17 1986 Low-risk Low-risk MTX
18 1987 Low-risk Low-risk MTX 
19^ 1987 High-risk High-risk EMACP
20^ 1991 High-risk High-risk EMA/CO 
21^ 1991 Low-risk High-risk MTX 
22^ 1992 High-risk High-risk EMA/CO 
23^ 1999 High-risk High-risk EMACP 
24 2000 Low-risk Low-risk MTX 
25 2008 High-risk High-risk Hysterectomy 
26^ 2010 Low-risk High-risk MTX 
†Risk classification according to Bagshawe available from 1977 onwards. Dutch classification system 
available from 1983 onwards.
‡Patients were classified according to the Dutch classification system
**Based on long interval from index pregnancy, high serum hCG values and  lung metastases
***MTX, actinomycin D, adriamycin, cytarabin, vincristine, cyclophosphamide
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that time, multi-agent chemotherapy should have been started, but instead MTX 
was started. The remaining three patients were classified as high-risk at the time, 
but MTX was the drug of choice in two patients because they were too ill to receive 
multi-agent chemotherapy (patients 9 and 11) and one patient refused multi-agent 
chemotherapy (patient 14).
 Nineteen patients were diagnosed with post-term GTN. According to the 
current Dutch guidelines, these patients would all be classified as having high-risk 
disease. Seven patients were classified as high-risk and treated accordingly. Twelve 
patients were not treated with multi-agent chemotherapy for various reasons.
Discussion
This study provides an overview of patients who died from GTN in the Netherlands, 
and  aimed to identify factors in the management that may have influenced the 
course of disease in these patients. A decline was observed in the yearly number of 
fatal cases over the last four decades, despite the increased incidence of GTD and 
GTN in the Netherlands.24 Several changes in the management of GTN during the 
study period contributed to this decline. Risk classification of patients into low- and 
high-risk disease, and introduction of multi-agent chemotherapy for high-risk 
patients caused a major decline in fatal cases as seen from 1971-1990. In addition, 
the classification and corresponding treatment of patients with post-term chorio-
carcinoma as high-risk patients most likely contributed to a decline in fatal cases. 
 Nineteen patients (73·1%) died from metastatic disease and in seven patients 
(26·9%) death was treatment related. Kingdon et al. reported comparable results 
from the United Kingdom with 68% death from metastatic tumour and 32% 
treatment related death.25 Most important cause of death in their study was 
metastatic multi-agent resistant PSTT. Although  incidences of PSTT are similar 
between the Netherlands and the UK, none of the deceased patients in the present 
study had PSTT.24,26
 Previously, Lurain et al. stated that death from GTN could mainly be attributed 
to the presence of extensive disease at the time of initial treatment, lack of initial, 
appropriately aggressive treatment in high-risk patients, and failure of chemotherapy 
protocols used at the time to control advanced disease.12 Appropriate risk 
classification is essential to start the right initial therapy and to prevent therapy 
resistance. In the present study, risk classification was sometimes difficult because 
of uncertain antecedent pregnancy. Some patients presented with an extensive 
time interval since the last diagnosed pregnancy and some of them additionally 
reported recent vaginal bleeding. This led to suspected, but undiagnosed abortion 
as the causative gestational event. Although rare, cases of GTN presenting many 
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years after the last pregnancy are described.27,28 Therefore, to prevent these patient 
from being undertreated, these patients should be considered as having post-term 
GTN. Other women in our study had a history of HM, with or without GTN, and had 
abortions or term pregnancies afterwards, leading to difficulties in determining the 
causative pregnancy. Previously, other authors demonstrated using molecular 
genetic techniques that the immediate antecedent pregnancy may not be the 
causative conception in some cases of choriocarcinoma.29;30 Genetic techniques are 
also used to differentiate gestational from non-gestational trophoblastic neoplasia. 
In our study, genetic techniques might have been helpful to differentiate between 
gestational and non-gestational tumours since clinical diagnosis often was not 
evident. Unfortunately, paraffin embedded tissue from these patients was not 
available.
 Our study revealed that uterine haemorrhage or haemorrhage from metastases 
was the most common cause of death (16/26). Previously, Lurain et al. also reported 
haemorrhage from metastases as the most common cause of death (42%).12 Early 
death occurred in nine patients and most of these patients presented with extensive 
disease. One patient died within four weeks from treatment related haemorrhage. 
Treatment related haemorrhage can occur in GTN because these tumours are highly 
vascularised and can easily start bleeding, for instance when a biopsy is taken or 
when fast necrosis occurs after administration of multi-agent chemotherapy.15 One 
patient died from tumourogenic pulmonary embolism within eight hours after 
initiation of treatment with moderately high doses of MTX, etoposide and cyclo-
phosphamide. Previously, other authors suggested that patients with large tumour 
loads might benefit from relatively mild initial treatment to prevent massive necrosis 
of the tumour leading to fatal haemorrhage or massive embolism.11,15 This might 
especially be true for patients not previously exposed to this type of chemotherapy.11 
Seckl et al. suggested initial low dose etoposide and cisplatin (EP) for 2 days combined 
with dexamethasone to reduce tumour oedema in patients with extensive disease.15 
Alifrangis et al. demonstrated that after introduction of low-dose EP in 1995, 23·1% 
of high-risk patients (34/147) with a high disease burden (FIGO >8 and >6 metastases) 
had received EP-induction chemotherapy, with a reduction in early deaths in 
high-risk patients from 7·2% in the pre-1995 cohort to 0·7% (n=1) after 1995.31 Other 
authors demonstrated the usefulness of angiographic embolisation in haemorrhage 
due to GTN.32-34 Pelvic haemorrhage, either uterine or vaginal, may be controlled by 
embolisation of the internal iliac vessels, and embolisation of the hepatic arteries 
may be performed to control bleeding from liver metastases.33,34 In acute hemorrhagic 
complications in GTN, this intervention should be considered to control bleeding. 
 Nineteen patients in our study died from post-term choriocarcinoma. In 1978 
Hammond was the first to propose antecedent term pregnancy as a poor prognostic 
indicator and subsequently added this into a clinical classification system.35,36 They 
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showed that post-term gestation classified as having a poor prognosis had a 
significantly lower cure rate (47%) than other patients classified as having a poor 
prognosis (75%, p<0.05).36 Lurain et al. also showed that GTN after term pregnancy, 
abortion or ectopic pregnancy has a significant lower cure rate than after HM (64% 
vs. 84%, respectively).12 In the Netherlands, patients with a choriocarcinoma after a 
term pregnancy are classified as high-risk.17 Before the introduction of this Dutch 
classification system in 1983, patients with GTN after a term pregnancy might also 
be classified as low-risk and were treated accordingly with single-agent chemo- 
therapy. In the FIGO 2000 system, patients with GTN after a term pregnancy are 
given two points. Since high-risk disease is defined as a score of ≥7, these patients 
might still be classified as low-risk. In our study, two patients with post-term GTN 
would have been classified as low-risk according to the FIGO 2000 criteria. Lok et al. 
reported MTX resistance in 75% of patients with post-term choriocarcinoma treated 
with MTX primarily. A subgroup of patients in which single-agent chemotherapy 
would be a safe alternative could not be determined. Additionally, an overall survival 
rate of 85% was found in patients with post-term choriocarcinoma, which is 
comparable to survival rates of high-risk disease in general.22 Therefore we propose 
that all patients with post-term GTN are classified as having high-risk disease. Lok et 
al. proposed the long interval between the index antecedent term pregnancy and 
start of treatment as an explanation for the high-risk status of patients with post 
term choriocarcinoma.22 A longer time interval between the antecedent pregnancy 
and the start of treatment is associated with lower survival rates.12 In addition, 
the long symptom free period may cause delay in diagnosis, because a possible 
diagnosis of choriocarcinoma may not be evident, especially since most physicians 
are relatively unfamiliar with choriocarcinoma.
 Strengths of this nationwide study lie in the long time period studied and 
detailed analysis of fatal cases. A limitation is the possibility of an underestimation 
of the number of fatal cases in the Netherlands, because registration in the DCRHM 
and Dutch Working Party is not obligatory and therefore not all deceased patients 
might be registered. In addition, we did not include a comparative group of patients 
that did not die from GTN, since our goal was to establish a description of a unique 
group of patients that died from GTN, and compare the management of these cases 
with the protocol or guideline at the time of diagnosis.  
 In conclusion, we found that the yearly number of fatal cases of GTN decreased 
considerably over the last four decades, despite the increased incidence of GTD. 
Several improvements in management contributed to this decrease. Appropriate 
risk classification is essential to start optimal initial therapy and prevent therapy 
resistance. Patients with extensive disease may benefit from relatively mild initial 
treatment to prevent massive necrosis of the tumour leading to fatal haemorrhage 
or massive embolism. Patients with post-term choriocarcinoma represented a large 
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part of the patients deceased and we propose that these patients, as in Dutch 
classification system, are considered as having high-risk disease.
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Abstract
Background: Cisplatin-based chemotherapy (etoposide 100mg/m2 day 1-5, methotrexate 
300mg/m2 day 1,  cyclophosphamide 600mg/m2 day 1, actinomycin D 0.6 mg/m2 day 
2 and cisplatin 60 mg/m2 day 4, EMACP) was compared to EMA/CO (etoposide 
100mg/m2 day 1-2, methotrexate 300mg/m2 day 1 and actinomycin D 0.5  mg i.v. 
bolus day 1 and 0.5  mg/m2 day 2, alternating with cyclophosphamide 600 mg/m2 
day 8 and vincristine 1 mg/m2 day 8) for the treatment of high-risk gestational 
trophoblastic neoplasia (GTN).
Methods:  In the Netherlands, 83 patients were treated with EMACP and 103 patients 
with EMA/CO. Outcome measures were remission rate, median number of courses 
to achieve normal human chorionic gonadotrophin (hCG) concentrations, toxicity, 
recurrent disease rate and disease specific survival.
Results: Remission rates were similar (EMACP 91.6%, EMA/CO 85.4%). The median 
number of courses of EMA/CO to reach hCG normalisation for single-agent resistant 
disease and primary high-risk disease were 3 and 5 courses, respectively, compared 
to 1.5 (p=0.001) and 3 (p<0.001) courses of EMACP. Patients treated with EMACP 
more often developed fever, renal toxicity, nausea and diarrhoea compared to 
patients treated with EMA/CO. Patients treated with EMA/CO more often had 
anaemia, neuropathy and hepatotoxicity.
Conclusion: EMACP combination chemotherapy is an effective treatment for 
high-risk GTN, with a remission rate comparable to EMA/CO. However, the difference 
in duration of treatment is only slightly shorter with EMACP. Cisplatin-based 
chemotherapy in the form of EMACP in this study was not proven more effective 
than EMA/CO.
Comparing cisplatin-based combination chemotherapy with EMA/CO for high-risk GTN | 87
6
Introduction
Gestational trophoblastic disease (GTD) comprises a spectrum of disorders, ranging 
from the premalignant complete and partial hydatidiform moles (CHM and PHM, 
respectively), to gestational trophoblastic neoplasia (GTN) consisting of invasive 
moles, choriocarcinoma, placental site trophoblastic tumours (PSTT) and the rare 
epithelioid trophoblastic tumour (ETT). Patients with GTN are classified as having 
low-risk or high-risk disease using the modified WHO prognostic scoring system as 
adapted by FIGO.[1] Patients with a score of 0-6 are defined as having low-risk 
disease. These patients are treated with single-agent chemotherapy, consisting of 
either methotrexate (MTX) or actinomycin D. For high-risk patients (prognostic 
score of 7 or more) single-agent chemotherapy is considered insufficient treatment 
and they are therefore treated with multi-agent chemotherapy.[2] 
 Before the introduction of multi-agent chemotherapy in the 1970s, only 31% of 
the high-risk patients would be cured with single-agent chemotherapy.[3] Throughout 
the late 1970s, the combination of MTX, actinomycin D, and cyclophosphamide or 
chlorambucil (MAC) became the preferred first-line chemotherapy, followed by the 
combination regimen of cyclophosphamide, hydroxyurea, actinomycin D, MTX, 
vincristine and doxorubicin (CHAMOCA) in the early 1980s.[2;4;5] In 1982, an 
alternative schedule to CHAMOCA was designed by the Dutch Working Party on 
Trophoblastic Disease, consisting of etoposide, MTX, actinomycin D, cyclophospha-
mide and cisplatin (EMACP), aiming to design a schedule that could be repeated 
frequently with a short interval between two courses, causing less myelosuppres-
sion and containing the new agents etoposide and cisplatin.[6;7] Today, the most 
widely accepted initial treatment for high-risk trophoblastic tumour is EMA/CO 
chemotherapy (etoposide, MTX and actinomycin D, alternating with cyclophospha-
mide and vincristine) introduced in 1979 by Newlands and Bagshawe, showing 
complete remission rates ranging from 69% to 86%.[8-11] However, due to the 
favourable outcome following treatment, some centres in the Netherlands preferred 
to continue application of the EMACP schedule after the introduction of EMA/CO. 
The aim of the present study was to evaluate the efficacy and safety of cisplatin-
based combination chemotherapy (EMACP) as compared to the EMA/CO schedule 
for the treatment of high risk GTN.
Methods
Patients
In the Netherlands, patients with GTD are registered at the Dutch Central Registry 
for Hydatidiform Moles (DCRHM) residing at the Radboud University Nijmegen 
Medical Centre (RUNMC). This voluntary registry serves as an epidemiological 
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database and provides a national human chorionic gonadotrophin (hCG) assay 
service to gynaecologists. Patients with GTD, and even GTN are treated in various 
referral hospitals. The Dutch Working Party on Trophoblastic Disease, founded in 
1971, has a registration and advisory function. The Dutch classification system for 
trophoblastic tumours scores for previous failure to chemotherapy, localisation of 
metastases, antecedent pregnancy and the interval between end of pregnancy and 
beginning of treatment (Table 1). Patients treated with EMACP or EMA/CO from 1982 
to 2009 were identified from the databases of the DCRHM and the Dutch Working 
Party on Trophoblastic Disease. Patients treated with other multi-agent chemo- 
therapy administered before the start of EMACP or EMA/CO, patients diagnosed 
with PSTT, and patients with a non-gestational tumour were excluded. In total, 83 
patients treated with EMACP and 103 patients treated with EMA/CO were included 
in this study. Medical records of all patients were reviewed for age at diagnosis, 
antecedent pregnancy, date of evacuation, histology of the tumour, localisation of 
metastases, indication for treatment with first multi-agent chemotherapy and 
duration of follow-up. 
Treatment
The EMACP and EMA/CO chemotherapy regimen are shown in Table 2. In the EMACP 
regimen, the interval between courses is twenty-one days. After normalisation of 
the serum hCG concentration generally two courses of chemotherapy were given to 
Table 1   Risk classification of GTN by the Dutch Working Party on Trophoblastic 
Disease.
Low-risk GTN Demands all of the following conditions: 
1.  Antecedent pregnancy: hydatidiform mole or abortion* 
2.  No metastases or metastases in vagina or lung  
3.  No previous chemotherapy 
4.  Interval between evacuation and start of chemotherapy less 
than 12 months 
High-risk GTN Demands one or more of the following conditions:
1.  Failure of previous (mono-) chemotherapy  
2.  Metastases in more than one site (outside the uterus)
3.  Metastases in one or more of the following organs: liver, 
spleen, kidney, gastrointestinal tract, bones or brain 
4.  Antecedent pregnancy: term
5.  Interval between end of antecedent pregnancy and start of 
chemotherapy more than 12 months
* There is no consensus on classification of non-molar abortion as low- or high-risk disease
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prevent disease relapse. In the EMA/CO regimen, interval between courses is 15 
days. After normalisation of the serum hCG the national guideline advises three 
courses of consolidation chemotherapy.[12] Drug resistance was defined as steady 
or increasing serum hCG during treatment. When drug resistance occurred most 
patients were treated with surgery, salvage  chemotherapy treatment or both.
Outcome measures
Outcome measures were the percentage of patients that achieved a complete 
remission, defined as a normal hCG value after completion of treatment (without 
consolidation courses), and the median number of chemotherapy courses required 
Table 2   (a) EMACP regimen and EMA/CO regimen for high-risk gestational 
trophoblastic neoplasia and (b) the accumulated dosage per week. 
Interval between courses is 21 and 15 days, respectively.
2a
EMACP regimen EMA/CO regimen
Day Chemotherapy Dose (i.v.) Day Chemotherapy Dose (i.v.)
1 Etoposide 100 mg/m2 1 Etoposide 100 mg/m2
Methotrexate 300 mg/m2 Methotrexate 300 mg/m2
Cyclophosphamide 600 mg/m2 Actinomycin D 0.5  mg 
2 Etoposide 100 mg/m2 2 Etoposide 100 mg/m2
Actinomycin D 0.6  mg/m2 Actinomycin D 0.5  mg
3 Etoposide 100 mg/m2 8 Vincristine 1     mg/m2 
4 Etoposide 100 mg/m2 Cyclophosphamide 600 mg/m2 
Cisplatin 60   mg/m2
5 Etoposide 100 mg/m2
2b 
EMACP regimen EMA/CO regimen
Etoposide 166.7 mg/m2 Etoposide 100 mg/m2
Methotrexate 100 mg/m2 Methotrexate 150 mg/m2
Cyclophosphamide 200 mg/m2 Cyclophosphamide 300mg/m2
Actinomycin D 0.2 mg/m2 Actinomycin D 0.5 mg
Cisplatin 20 mg/m2 Vincristine 0.5 mg/m2
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to achieve complete remission. Also, the percentage of patients with recurrent 
disease and the disease specific survival was registered after 24 months of follow-up 
from the start of treatment. The cut-off point of 24 months was chosen because the 
national guidelines recommend two years of follow-up after treatment for high-risk 
GTN, since the chance of relapsed disease is the highest within the first year of 
remission, and 85% of all episodes of disease relapse occur within 18 months of 
remission.[12;13] Short-term toxicities were registered according to the Common 
Terminology Criteria for Adverse Events v3.0 (CTCAE). Also long-term toxicities, 
including secondary malignancies were registered. Data on toxicity were obtained 
from the medical records and if used, from the Systemic Therapy Checklist designed 
by the EORTC.[14]
Statistical analysis
Statistical analysis was performed using SPSS software (version 18). Patient charac-
teristics, remission rates and toxicity were compared using Chi-square test. Mean 
age was compared using Student’s t-test. The median number of chemotherapy 
courses to hCG normalisation were compared using the non-parametric independ-
ent-samples median test. P values of less than 0.05 were considered statistically 
significant.
Results
Patient characteristics are shown in Table 3. In total, 83 patients were treated with 
EMACP, of which 16 patients received a modified schedule without MTX (ECAP). 
Patients treated with EMA/CO were significantly older (mean 32 years) than patients 
treated with EMACP (mean 29 years, p=0.008). The antecedent pregnancies from 
patients treated with EMACP were not significantly different from patients treated 
with EMA/CO. The indications for treatment were significantly different between 
patients treated with EMACP and those treated with EMA/CO (p=0.023). Patients 
treated with EMACP more often were treated for single-agent resistant disease 
(63.9%) compared to EMA/CO patients (43.7%). More patients treated with EMA/CO 
had primary high-risk disease (42.7%) compared to patients treated with EMACP 
(27.7%). Seven patients (8.4%) were treated with EMACP and 14 patients (13.6%) with 
EMA/CO because of disease relapse after single-agent chemotherapy. Median 
follow-up from the start of treatment was 33.3 months (range 3.9–246.9 months).
Acute toxicity
Table 4 shows toxicity profiles for EMACP and EMA/CO. Three patients died from 
sepsis related to treatment, of which one patient was treated with EMACP and two 
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6were treated with EMA/CO. Patients treated with EMACP more often developed fever (22.9% vs. 11.7%, p=0.041), renal toxicity (15.7% vs. 4.9%, p=0.013), nausea 
(48.2% vs. 28.2%, p=0.005) and diarrhoea (13.3% vs. 3.9% p=0.02) compared to 
patients treated with EMA/CO. Patients treated with EMA/CO more often had 
anaemia (28.8% vs. 7.2%, p<0.001), although the incidence of leucopenia and throm-
bocytopenia was not significantly different. In addition, they more often developed 
neuropathy (26.2% vs. 6.0%, p<0.001) and hepatotoxicity (16.5% vs. 6.0%, p=0.028). 
 The number of patients in whom the dose of chemotherapy had to be reduced 
was not significantly different between EMA/CO and EMACP (21.4% versus 27.7%), 
but in more patients treated with EMACP one or more courses had to be delayed due 
to toxicity or myelosuppression (36.1% versus 20.4%, p=0.017). In patients treated 
with EMACP, a total of 330 courses were administered. Patients treated with EMA/
CO received a total of 688 courses. Dose reduction occurred in 39 (11.8%) of EMACP 
courses and in 60 (8.7%) of EMA/CO courses (mostly removal of vincristine due to 
neuropathy) (p=0.119). Delay of chemotherapy was required in 45 courses (13.6%) of 
EMACP, compared to 33 (4.8%) of EMA/CO courses that were given with delay 
(p<0.001).
Table 3   Patient characteristics.
EMACP 
(n=83)
EMA/CO 
(n=103)
p
Age at diagnosis (y)
          Mean (SD) 29  (6) 32 (6.2)
0.008
Antecedent pregnancy NS
            Hydatidiform Mole 62  (74.7%) 59  (57.3%)
            Term pregnancy 17  (20.5%) 38  (36.9%)
            Non-molar abortion 2    (2.4%) 4    (3.9%)
            Uncertain 2    (2.4%) 2    (1.9%)
Indication for treatment 0.023
            Single-agent resistant disease 53  (63.9%) 45 (43.7%)             
            Primary high-risk disease 23  (27.7%) 44 (42.7%)  
            Disease relapse after MTX 7    (8.4%) 14 (13.6%)
SD standard deviation
MTX Methotrexate
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Late toxicity
In total, seven patients developed secondary malignancies, of whom two patients 
died. After EMA/CO, 4 patients developed a secondary malignancy (3.9%): 2 Acute 
Myeloid Leukaemia (AML), 1 patient developed Chronic Myeloid Leukaemia (CML), 
and 1 patient died from multiple myeloma sixteen years after treatment with EMA/
CO. Three patients developed a secondary tumour after EMACP (3.6%). One 
developed myelodysplastic syndrome (refractory anaemia with excess blasts 
(RAEB)), and 2 patients developed AML, of which 1 patient died, 40 months after 
start of treatment. None of the patients had a cumulative etoposide dose exceeding 
2g/m2.
Response to treatment
Table 5 shows remission rates achieved with EMACP and EMA/CO for single-agent 
Table 4   Toxicity profile for EMACP (n=83) and EMA/CO (n=103).
EMACP EMA/CO 
Toxicity Number  
of patients (%)
Number  
of patients (%)
P
Myelosuppression
          Anaemia 6    (7.2%) 29   (28.2%) <0.001
          Leucopoenia 50  (60.2%) 50   (48.5%) NS
          Thrombocytopenia 6    (7.2%) 4     (3.9%) NS
Fever 19  (22.9%) 12   (11.7%) 0.041
Neuropathy 5    (6.0%) 27   (26.2%) <0.001
Renal toxicity 13  (15.7%) 5     (4.9%) 0.013
Hepatotoxicity 5    (6.0%) 17   (16.5%) 0.028
Gastro-intestinal
         Mucositis 16  (19.3%) 10   (9.7%) NS
         Nausea 40  (48.2%) 29   (28.2%) 0.005
         Diarrhoea 11  (13.3%) 4     (3.9%) 0.02
Dose reduction 23  (27.7%) 22   (21.4%) NS
Delay in courses 30  (36.1%) 21   (20.4%) 0.017
Secondary malignancy 3    (3.6%) 4     (3.9%) NS
Death 1    (1.2%) 2     (1.9%) NS
NS not significant
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resistant disease, primary high-risk disease, and relapsed disease after initial 
remission on single-agent chemotherapy. In total, 76 out of 83 patients achieved 
disease remission with EMACP (91.6%), compared to 88 out of 103 patients treated 
with EMA/CO (85.4%), which was not significantly different. Remission was achieved 
in 52 of 53 (98.1%)  patients that were treated with EMACP after failure of initial 
single-agent chemotherapy, compared to 44 of 45 (97.8%) in patients treated with 
EMA/CO, which was not significantly different. Median number of EMACP courses 
to achieve normal serum hCG concentrations in these patients was 1.5 (range 1-5) 
compared to a median of 3 (range 1-6) courses of EMA/CO (p=0.001). In 78.3% (18 
out of 23) and 72.7% (32 out of 44) of patients that were primarily classified as 
high-risk GTN, disease remission was achieved with EMACP and EMA/CO, 
respectively (not significant). They received a median of 3 EMACP courses (range 
2–7) and 5 EMA/CO courses (range 3-13) to achieve normal serum hCG concentrations 
(p<0.001). In 85.7% (6 out of 7) of patients treated for disease relapse after 
single-agent chemotherapy disease remission was achieved with a median of 1 
course of EMACP. Complete remission was also achieved in 85.7% (12 out of 14) of 
these patients treated with EMA/CO, but with a median of 2 (range 1-4) courses (not 
significantly different). The median duration of treatment to achieve disease 
remission for single-agent resistant disease, primary high risk disease and relapsed 
disease, respectively, is 6, 10 and 4 weeks with EMA/CO, compared to 4.5, 9 and 3 
weeks with EMACP.
 Of the 17 patients treated with EMACP for post-term GTN, 14 went into remission 
(82.4%) with a median of 3 courses. Of the 38 patients treated with EMA/CO that 
had an antecedent term pregnancy, 28 patients (73.7%) went in remission (data not 
shown). These patients received a median of 5 courses of EMA/CO to achieve 
normalisation of the hCG concentration (range 1-13). During follow-up, 10 patients 
out of 76 patients that initially went into remission with EMACP subsequently 
developed recurrent disease (13.2%), compared to 4 out of 88 patients that achieved 
disease remission with EMA/CO (4.5%, p=0.049). 
 Seven patients did not achieve disease remission with EMACP. Two patients had 
an additional hysterectomy and one patient was switched to EMA/CO due to severe 
toxicity of EMACP. One patient developed a severe sepsis and died after the first 
EMACP course. Another patient was wrongfully switched to EMACO due to presumed 
drug resistance, however, this was due to the use of another hCG assay. In 1 patient 
the hCG concentration was decreasing but upfront she agreed on performing a 
hysterectomy if after 4 courses of EMACP the hCG was not normalised. One patient 
initially treated with EMACP, died from metastatic disease 23 months after diagnosis. 
She presented with a choriocarcinoma after a term pregnancy with metastases to 
liver and lungs, and was treated with extensive chemotherapy and radiotherapy but 
subsequently developed bone and brain metastases. 
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 Fifteen patients did not achieve disease remission with EMA/CO. Seven patients 
were switched to a platinum-containing chemotherapy regimen. Five patients were 
treated with a platinum-containing chemotherapy regimen and hysterectomy. Two 
patients died during EMA/CO due to sepsis, and 1 patient was cured with a hyster- 
ectomy only. 
 Five patients died from GTN or the given treatment within the 24 months of 
follow-up. Disease specific survival of EMACP patients was 96.4% (80 out of 83) and 
98.1% (101 out of 103) of patients initially treated with EMA/CO.
Discussion
The present study showed that 91.6% of patients treated with EMACP achieved 
disease remission compared to 85.4% of patients treated with EMA/CO. Patients 
treated for primary high-risk disease, single-agent resistant disease and relapsed 
disease all required less courses of EMACP to achieve normalisation of serum hCG 
compared to patients treated with EMA/CO. Patients treated with EMACP more 
often developed fever, renal toxicity and gastro-intestinal toxicity, and significantly 
more courses had to be delayed compared to EMA/CO. However, patients treated 
with EMA/CO more often had anaemia, neuropathy and hepatotoxicity. The number 
of patients that died from sepsis during treatment and of patients that developed 
secondary tumours was comparable in EMA/CO en EMACP.
 In previous studies evaluating EMA/CO combination chemotherapy, a remission 
rate of 69% to 86% was obtained.[8-10;15-18] The disease specific survival rate varies 
from 85% to 90.9%. [8;9;16;17] The remission rate and disease specific survival of all 
EMA/CO patients in our study were 85.4% and 98.1%, respectively. In the present 
study more patients treated with EMA/CO had primary high-risk disease compared 
to patients treated with EMACP. Remission rates were higher in patients who 
received prior single-agent chemotherapy compared to patients that received EMA/
CO as first treatment for primary high-risk disease (97.8% versus 72.7% respectively). 
For comparison, Escobar et al. found that the complete response to EMA/CO was 
higher in patients who received EMA/CO as primary treatment (76%) than in 
patients who were treated secondarily with EMA/CO (65%).[18] In contrast, Bower 
et al. reported that the complete remission rate after EMA/CO was not different if 
women received prior chemotherapy (78% and 79% for first and second line 
treatment).[8] Lu et al. also found the same remission rates in patients receiving 
EMA/CO as first-line treatment and as secondary treatment (77.8%).[16] The 
differences found in our study might result from a difference in prior chemotherapy. 
Patients that received prior chemotherapy in the studies by Bower et al. and Lu et al. 
had received either single-agent MTX or combination chemotherapy, whereas all 
patients in our study only received previous single-agent MTX or actinomycin D.
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 Although less courses of EMACP than EMA/CO were needed to achieve normal 
serum hCG, EMACP is a three-weekly schedule whereas EMA/CO is a two-weekly 
schedule. Still, the duration of chemotherapeutic treatment, although minimal, is 
shorter with EMACP. However, each course of EMA/CO requires only one day of 
hospital admittance every two weeks for the administration of the EMA part of the 
course, since the CO part on day 8 can be given in the outpatient clinic. In contrast, 
administration of the EMACP schedule requires five days of hospital admittance 
(day 1 to 5) every three weeks, which is a higher burden for the patient and is less 
cost-effective. In this respect, EMA/CO therefore seems preferable over EMACP. If 
the difference in number of consolidation courses would be included, patients 
treated with EMACP, who received two consolidation courses, would have received 
3.5, 5 and 3 courses for single-agent resistant disease, primary high risk disease and 
relapsed disease, respectively, compared to 6, 8 and 5 courses of EMA/CO, since for 
the EMA/CO regimen three consolidation courses are advised. However, significantly 
more patients developed recurrent disease after EMACP (13.2%) than after EMA/CO 
(4.5%), which may warrant the need for three courses of consolidation therapy of 
EMACP to obtain sustained remission.
 The relatively high risk of developing secondary malignancy found is most likely 
brought about by etoposide.[19] Perdersen-Bjergaard et al. reported on 5 patients 
with leukemic complications among 82 patients who received a cumulative dose of 
more than 2 g/m2 etoposide, whereas no leukaemia’s were observed among 130 
patients who had received up to 2 g/m2.[20;21] Each course of EMA/CO contains 200 
mg/m2 of etoposide compared to 500 mg/m2 in the EMACP schedule. Therefore the 
cumulative dose of 2g/m2 is reached after four courses of EMACP and only after ten 
courses of EMA/CO. All three patients that developed secondary tumours after 
EMACP received four courses of EMACP. Of the four patients who developed 
secondary malignancies after EMA/CO, in none of the patients this dose was 
reached. However, more recent reports suggest that the risk estimate after moderate 
cumulative doses (1.5-3 g/m2) was virtually identical to the risk estimate for patients 
who received etoposide at a dose of less than 2.0g/m2.[22] Etoposide is a cell-cycle 
specific agent, and large differences have been reported for different schedules. A 
schedule of five consecutive daily infusions is much more active than 24-h infusion 
of the same total dose.[23] Similarly, increased leukemogenicity was suggested for 
these intermittent administration schedules. 
 Cisplatin has previously been identified as an active agent for high-risk GTN.[24] 
Currently, it is used in patients who have failed initial combination chemotherapy in 
particular, such as the EMA/EP regimen, substituting etoposide and cisplatin for cy-
clophosphamide and vincristine in the EMA/CO protocol. EP and EMA are alternated 
at weekly intervals.[24] In contrast to EMACP, EMA/EP does not contain cyclophos-
phamide. In addition, EMA/EP contains a cumulative dose of 250 mg/m2 etoposide in 
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each course, compared to 500 mg/m2 in the EMACP schedule. However, EMA/EP 
contains 75 mg/m2 cisplatin in each course compared to 60 mg/m2 cisplatin in the 
EMACP schedule. Previously, Newlands et al. reported significant toxicity of EMA/EP 
chemotherapy in patients who have relapsed after or who have become refractory 
to EMA/CO, with patients suffering from neutropenia (68%), thrombocytopenia 
(40%), anaemia (21%) and renal toxicity (41%). Myelosuppression caused delays in 
chemotherapy in 88% of EMA/EP patients and 38% of patients required dose 
reductions.[25] Mao et al. reported myelosuppression and gastro-intestinal problems 
as the main adverse effects in 18 patients treated with 74 cycles of EMA/EP. Because 
of myelosuppression and hepatotoxicity, 32 courses (43.2%) were delayed.[26] This is 
a much higher toxicity than the observed toxicity of EMACP in our study. Adding 
cisplatin after previous multi-agent chemotherapy leads to an impaired bone 
marrow reserve. It might therefore be advantageous to start chemotherapy with 
cisplatin earlier in the course of treatment. 
 In conclusion, EMACP combination chemotherapy is an effective treatment for 
high-risk GTN. The remission rate of EMACP was comparable to EMA/CO, and 
although less courses of EMACP were required to achieve disease remission, the 
difference in duration of chemotherapeutic treatment is only slightly shorter with 
EMACP. Short term toxicity was alternating different between EMACP and EMA/CO, 
but overall not significantly more common in either of them, whereas long-term 
toxicity was not different between both regimens. Cisplatin-based chemotherapy in 
the form of EMACP in this study was not proven more effective than EMA/CO. From 
the results of this study no arguments could be found to change the current standard 
with EMACO.
98 | Chapter 6 Comparing cisplatin-based combination chemotherapy with EMA/CO for high-risk GTN | 99
References
1  FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol 
Obstet 2002; 77: 285-7.
2 Lurain JR. Gestational trophoblastic disease II: classification and management of gestational 
trophoblastic neoplasia. Am J Obstet Gynecol 2010; 204: 11-8
3  Bagshawe KD, Dent J, Newlands ES, et al. The role of low-dose methotrexate and folinic acid in 
gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989; 96: 795-802.
4  Begent RH, Bagshawe KD. The management of high-risk choriocarcinoma. Semin Oncol 1982; 9: 198-203.
5  Lurain JR, Brewer JI. Treatment of high-risk gestational trophoblastic disease with methotrexate, 
actinomycin D, and cyclophosphamide chemotherapy. Obstet Gynecol 1985; 65: 830-6.
6  Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination 
chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8.
7  Newlands ES, Bagshawe KD. Activity of high-dose cis-platinum (NCI 119875) in combination with 
vincristine and methotrexate in drug-resistant gestational choriocarcinoma. A report of 17 cases. Br J 
Cancer 1979; 40: 943-5.
8  Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results 
from a cohort of 272 patients. J Clin Oncol 1997; 15: 2636-43.
9  Newlands ES, Bagshawe KD, Begent RH, et al. Results with the EMA/CO (etoposide, methotrexate, 
actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 
1979 to 1989. Br J Obstet Gynaecol 1991; 98: 550-7.
10  Bolis G, Bonazzi C, Landoni F, et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). 
Gynecol Oncol 1988; 31: 439-44.
11  Newlands ES, Bagshawe KD, Begent RH, et al. Developments in chemotherapy for medium- and high-risk 
patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol 1986; 93: 63-9.
12  Werkgroep Oncologische Gynaecologie (WOG). Landelijke Richtlijn Persisterende trofoblast en chorio-
carcinoom. www.oncoline.nl 2010 July 13 (version 1.3)
13  Mutch DG, Soper JT, Babcock CJ, et al. Recurrent gestational trophoblastic disease. Experience of the 
Southeastern Regional Trophoblastic Disease Center. Cancer 1990; 66: 978-82.
14  Verweij J, Nielsen OS, Therasse P, van Oosterom AT. The use of a systemic therapy checklist improves the 
quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and 
Bone Sarcoma Group. Eur J Cancer 1997; 33: 1045-9.
15  Soper JT, Evans AC, Clarke-Pearson DL, et al. Alternating weekly chemotherapy with etoposide-metho-
trexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. 
Obstet Gynecol 1994; 83: 113-7.
16  Lu WG, Ye F, Shen YM, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a 
clinical analysis of 54 patients. Int J Gynecol Cancer 2008; 18: 357-62.
17  Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, 
cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol 
Cancer 2006; 16: 1432-8.
18  Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with 
etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol 
Oncol 2003; 91: 552-7.
19  Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of 
antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011; 19: 43-47.
20  Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for 
gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996; 14: 2769-73.
21  Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after 
treatment with epipodophyllotoxins. J Clin Oncol 1999; 17: 569-77.
22  Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia 
after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359-63.
Comparing cisplatin-based combination chemotherapy with EMA/CO for high-risk GTN | 99
6
23  Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of 
etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333-40.
24  Theodore C, Azab M, Droz JP, et al. Treatment of high-risk gestational trophoblastic disease with 
chemotherapy combinations containing cisplatin and etoposide. Cancer 1989; 64: 1824-8.
25 Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and 
actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors 
refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with 
metastatic placental site trophoblastic tumors. J Clin Oncol 2000; 18: 854-9.
26  Mao Y, Wan X, Lv W, Xie X. Relapsed or refractory gestational trophoblastic neoplasia treated with the 
etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Int J Gynaecol 
Obstet 2007; 98: 44-7.
7
C. Lybol
K. Westerdijk
C.G.J. Sweep
P.B. Ottevanger
L.F.A.G. Massuger
C.M.G. Thomas
Annals of Oncology 2012; 23: 2903-6
Human chorionic gonadotropin (hCG) 
regression normograms for patients 
with high-risk gestational trophoblastic 
neoplasia treated with EMA/CO 
(etoposide, methotrexate, actinomycin D, 
cyclophosphamide, and vincristine) 
chemotherapy
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Abstract
Background We present normograms for human chorionic gonadotropin (hCG) 
regression in patients with high-risk gestational trophoblastic neoplasia (GTN) 
successfully treated with multi-agent chemotherapy in order to predict treatment 
resistance.
Methods We collected data for 46 patients with high-risk GTN treated with EMA/
CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) 
who had hCG values available. Patients were classified as having methotrexate 
(MTX)-resistant disease (n=22) or primary high-risk disease (n=24). The 10th, 50th 
and 90th percentiles of the hCG before every chemotherapy course were calculated 
and plotted into normograms.
Results Half of the patients treated for MTX-resistant disease and primary high-risk 
disease had normal hCG levels before the third and sixth course of chemotherapy, 
respectively. In patients with MTX-resistant disease, the 90th percentile line fell 
below normal before the start of the fourth course, whereas in patients with primary 
high-risk disease this was not the case until the eighth course of chemotherapy.
Conclusion Resistance to EMA/CO treatment for high-risk GTN, as illustrated by 
examples, could be predicted using normograms for hCG resistance. Normograms 
differed depending on the indication for multi-agent chemotherapy due to much 
higher initial hCG values in patients with primary high-risk disease compared with 
those treated for MTX-resistant disease. 
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Introduction
Gestational trophoblastic neoplasia (GTN) represents a unique group of tumours 
which includes invasive mole, choriocarcinoma, placental-site trophoblastic tumour 
(PSTT) and epithelioid trophoblastic tumour. GTN may arise in association with any 
pregnancy event, although ~50% are diagnosed after a hydatidiform mole. Patients 
with GTN are classified as having low-risk or high-risk disease using the modified 
World Health Organisation prognostic scoring system as adapted by the International 
Federation of Gynaecology and Obstetrics.1 Patients scoring ≥7 are considered to be 
at high risk of developing resistance to single-agent methotrexate (MTX), and are 
therefore treated with multi-agent chemotherapy. Worldwide, the most frequently 
used chemotherapy  is  EMA/CO (etoposide, MTX and actinomycin D, alternated weekly 
with cyclophosphamide and vincristine). The remission rate of EMA/CO ranges from 
71% to 86%.2-5 Patients who progress during the EMA/CO therapy have a poor 
outcome with a reported 5-year survival of only 43% (95% confidence interval (CI) 
12%-73%).6
 Currently an international definition of resistance to chemotherapy is lacking. 
Previously, van Trommel et al. developed a normogram for the regression of human 
chorionic gonadotropin (hCG) concentrations during the treatment of low-risk GTN 
with MTX to identify resistance to MTX at an early stage.7 This normogram allows 
the identification of 50% of patients needing alternative therapy with a specificity 
of 97.5% before the fourth course of MTX. The early identification of patients 
resistant to multi-agent chemotherapy is even more important, since these patients 
are at greater risk of a fatal outcome. For these patients, treatment options are 
limited. Salvage chemotherapy with etoposide and platinum drug regimens often 
combined with surgical excision of persistent tumour will result in remission in 
70%-88% of patients resistant to EMA/CO.2;8-11 We aimed at constructing normograms 
for hCG regression in patients with high-risk GTN successfully treated with EMA/CO 
chemotherapy in order to predict patients developing resistance to EMA/CO in an 
early phase of their treatment.
Methods
Patients
In the Netherlands, patients with gestational trophoblastic disease are registered 
voluntarily at the Dutch Central Registry for Hydatidiform Moles (DCRHM), which 
also provides a national hCG assay service to gynaecologists. A total of 4,190 patients 
were registered at the DCRHM from 1977 until 2012. Furthermore, patients with 
high-risk GTN are presented at the Dutch Working Party on Trophoblastic Disease. 
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Since 1983 in the Netherlands, a clinical classification system proposed by the Dutch 
Working Party has been used which defines high-risk disease as the presence of one 
or more of the following features: insufficient response to single-agent chemo therapy; 
metastasis in more than one organ; metastasis in liver, spleen, kidneys, gastro-intestinal 
tract, bones or brain; antecedent term pregnancy and an interval of >12 months 
between the end of the antecedent pregnancy and the start of treatment.12
 Data for all patients with high-risk GTN according to Dutch guidelines and 
treated with EMA/CO chemotherapy were collected from the databases of the 
DCRHM and the Dutch Working Party and included in the study. Patients receiving 
EMA/CO for recurrent disease were excluded. In addition, patients for whom the 
serum hCG values during EMA/CO treatment were unavailable or measured on an 
assay other than the in-house developed radioimmunoassay (RIA) of the assay 
service of the DCRHM were excluded from further analysis. Eventually, a total 
number of 46 patients treated with EMA/CO and with available hCG values were 
included in this study. 
 Based on the indication for treatment with multi-agent chemotherapy, patients 
were classified as having single-agent MTX-resistant disease (n=22) or as having a 
high prognostic score at the time of diagnosis of GTN (n=24). MTX resistant disease 
was defined as a rise or plateau in the hCG concentration during treatment with 
MTX for low-risk disease. Three patients with primary high-risk disease were treated 
with a hysterectomy before EMA/CO treatment, and one patient had a hysterectomy 
during EMA/CO treatment since she no longer wished to conceive. Separate 
normograms were constructed for patients receiving multi-agent chemotherapy 
due to MTX resistance and patients treated for primary high-risk disease at diagnosis 
of GTN. 
hCG measurements
All hCG concentrations were measured using an in-house developed RIA based on 
polyclonal antibody raised in rabbits.13 This assay detects intact hCG and free 
β-subunit: hCG+hCGβ. A highly purified hCG β-subunit preparation labelled with 
iodine-125 was employed as a tracer for this assay. The RIA was calibrated with the 
third International Standard Preparations for intact hCG and hCG β-subunit. A value 
of 2 ng/ml is considered normal. hCG concentrations that were measured in serum 
obtained before the start of a chemotherapy course were used in the construction 
of the normogram. However, hCG concentrations that were measured in serum 
obtained during a  chemotherapy course were excluded.
Statistics
All hCG measurements of the patients reaching complete remission after multi-agent 
chemotherapy without recurrent disease were used to construct the normograms 
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for MTX-resistant disease and for primary high-risk GTN. Log transformation was 
carried out on all hCG values to obtain normal distribution of the data. The hCG values 
were evaluated cross-sectionally for each chemotherapy course. The normograms 
were based on a minimum of 10 log-transformed hCG values for each chemotherapy 
course. Serum hCG concentrations were subsequently sorted for each chemotherapy 
course. The 10th, 50th and 90th percentiles for every chemotherapy course were 
calculated and plotted for each course in a normogram using Excel (Microsoft). 
Resistance to EMA/CO according to the normogram was defined as the hCG 
concentration exceeding the 90th percentile of the normogram. Statistical analysis 
was carried out using SPSS 18 software. Serum hCG concentrations before the first 
course of EMA/CO and the number of chemotherapy courses were compared using 
the Mann- Whitney U test. 
Results
The characteristics of patients with MTX-resistant disease and patients with primary 
high-risk disease are shown in Table 1. The median follow-up was 26.1 months for 
patients with MTX-resistant disease and 26.0 months for patients with primary 
high-risk disease. No patients who achieved normal hCG concentrations with EMA/
CO chemotherapy relapsed during follow-up.
 The normogram for patients treated with EMA/CO for MTX-resistant disease 
(n=22) is shown in Figure 1(a). The median hCG concentration before the onset of 
the first chemotherapy course was 21 ng/ml (range 3-1300 ng/ml), and before the 
third EMA/CO course half of the patients had normal hCG levels. The 90th percentile 
was at 148 ng/ml before the start of treatment. Ninety percent of the patients with 
MTX-resistant disease had normal hCG values before the start of the fourth EMA/
CO course. The 10th percentile is just above normal (3 ng/ml) before the start of the 
first course but decreases to normal levels before the second course. 
 The normogram for patients treated with EMA/CO for primary high-risk disease 
is shown in Figure 1(b). The 90th percentile before the start of treatment was 32,781 
ng/ml. In 90% of patients, hCG concentrations regressed to normal before 
commencing the eighth course of EMA/CO. The median hCG level was 7059 ng/ml 
(range 300-60,000 ng/ml) at the start of the first course, and after five EMA/CO 
courses 50% of patients had a normal hCG concentration. The 10th percentile line 
started at an hCG concentration of 1520 ng/ml, and ten percent of patients showed 
disease remission before the fourth course. 
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The median serum hCG concentration before the first course of EMA/CO was 
significantly less elevated (21 ng/ml) in the group of patients with MTX-resistant 
disease (n=19) compared with the group of patients with primary high-risk disease 
(7059 ng/ml, n=14) (p<0.001). Significantly fewer courses of EMA/CO were 
administered to the group of patients with MTX-resistant disease (n=22) (median 5 
courses; range 2-10) compared with the primary high-risk patients (n=22) (median 8 
courses; range 5-12; p<0.001). 
Table 1   Patient characteristics.
Methotrexate (MTX)- 
resistant disease 
(n=22)
Primary  
high-risk disease 
(n=24)
Age (years)
          Median (range) 31  (23-43) 29 (22-54)
Antecedent pregnancy
         Hydatidiform mole 22  (100%) 3   (12.5%)
         Term 0    (0%) 20 (83.3%)
         Non-molar abortion 0    (0%) 1   (4.2%)
Site of metastases**
         None 18  (81.8%) 8   (33.3%)
         Lungs 3    (13.6%) 15 (62.5%)
         Vagina 0    (0.0%) 4   (16.7%)
         Liver 1*  (4.6%) 0   (0.0%)
         Brain 0    (0.0%) 2   (8.3%)
Interval from index pregnancy to 
start EMA/CO treatment (months)
           <4 8  (36.4%) 16 (66.7%)
           4-6 10 (45.4%) 2   (8.3%)
           7-12 4  (18.2%) 1   (4.2%)
           >12 0   (0.0%) 5   (20.8%)
Serum hCG before start EMA/CO 
treatment (ng/ml)
          Median (range) 21 (3-1300) 7059 (300-60,000)
*Dubious lesion on computed tomography scan
** Some patients had metastases at several sites
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 Two primary high-risk patients failed to achieve normal hCG concentrations 
with EMA/CO. In one patient, there was a plateau of serum hCG after fi ve courses of 
EMA/CO. Subsequent chemotherapy consisted of three courses of EMA/EP, one 
course of VIP (etoposide, ifosfamide and cisplatin) and salvage surgery consisting of 
a hysterectomy and surgical excision  of pulmonary metastases. Her hCG level 
subsequently regressed to normal. The hCG concentration at the onset of EMA/CO 
Figure 1   Normogram for patients treated with EMA/CO (etoposide, methotrexate, 
actinomycin D, cyclophosphamide and vincristine) chemotherapy for 
methotrexate (MTX)-resistant disease (A) and for primary high-risk 
disease (B). The lower, middle and upper lines indicate the 10th, 50th 
and 90th percentiles. The number of hCG values the percentiles were 
calculated from is shown above each course. Patients not cured on EMA/
CO are plotted.
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was between the 50th and 90th percentile line, but the level exceeded the 90th 
percentile before the second course. The other patient also received five courses of 
EMA/CO, after which a plateau of serum hCG developed. Treatment was continued 
with four courses of VIP and a hysterectomy, after which the hCG level was normal. 
The serum hCG level in this patient exceeded the 90th percentile already before the 
start of treatment. 
Discussion 
In the present study, we constructed two normograms for the prediction of 
resistance to EMA/CO chemotherapy. As shown, normograms for hCG regression 
during multi-agent treatment differed depending on the indication for multi-agent 
chemotherapy. The  initial hCG concentrations in the group of patients with primary 
high-risk disease are much higher due to the higher tumour load compared with 
those in the MTX-resistant group of patients, who already had tumour regression 
with MTX and subsequent decrease of the hCG concentration. It is therefore 
important that hCG concentrations of patients with MTX-resistant disease and 
patients with primary high-risk disease are not combined into one normogram.
 Previous normograms for the prediction of postmolar GTN and for the prediction 
of resistance to MTX chemotherapy used upper percentiles of p95, p97.5 and p99, 
respectively.7;14;15 Early prediction of patients who will not be cured by multi-agent 
chemotherapy is of utmost importance to avoid fatal outcomes by an early change 
to a platinum-containing regimen  (usually EMA-EP). Therefore, the 90th percentile 
was chosen as the upper line of the normogram. We feel that early prediction of 
a larger portion  of patients not showing disease remission on EMA/CO outweighs 
the fact that more people will unnecessarily be treated with more toxic platinum- 
containing chemotherapy regimens. Patients with an hCG level >90th percentile of 
the normogram before the start of EMA/CO might be considered to start a platinum- 
containing chemotherapy regimen.
 We presented for the first time a normogram for hCG regression in patients 
with high-risk GTN successfully treated with EMA/CO  chemotherapy in order to 
predict treatment resistance. In addition, we demonstrated examples of two 
patients who could have been predicted early  as developing resistance to treatment. 
We showed that normograms for hCG regression differed depending on the 
indication for multi-agent chemotherapy due to higher  hCG values in the group of 
patients with primary high-risk disease compared with those with MTX-resistant 
disease. Our findings need to be validated in a larger cohort of patients.
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The main aim of the present thesis was to further optimise the management of 
patients with GTN by attempting to predict post-molar GTN and resistance to 
multi-agent chemotherapy.
Implications for the management of GTN
Staging: increasing role for antecedent term pregnancy 
The current FIGO 2000 staging and risk factor scoring system results from a merge 
of the basic anatomic FIGO staging from 1992 and the risk factor scoring system of 
the World Health Organisation (WHO).1-3 The latter had been adopted by the WHO 
in 1982 from the earlier system invented by Bagshawe.4 Unlike the FIGO 2000 scoring 
system, the Dutch classification system does not include scorings for age, 
pre-treatment serum hCG concentration, the number of metastases and largest 
tumour size.3;5 In contrast to the FIGO system, the Dutch classification system uses a 
number of absolute criteria and attaches more importance to a term pregnancy as 
the index pregnancy. This risk factor in itself has sufficient weight to classify the 
patient as having high-risk disease, whereas in the FIGO scoring system, only two 
points are allocated to patients with a term antecedent pregnancy. Since high-risk 
disease is defined as a score of ≥7, these patients might still be classified as having 
low-risk GTN. In 1978, Hammond was the first to propose an antecedent term 
pregnancy as a poor prognostic indicator and subsequently added this into a clinical 
classification system.6;7 He showed that 47% (7 out of 15) of patients with high-risk 
metastatic GTN with a post-term gestation were cured compared to 75% (48 of 63; 
p<0.05) of other patients with high-risk metastatic disease.7 Lurain et al. also showed 
that GTN after term pregnancy, abortion or ectopic pregnancy had a significantly 
lower cure rate than after HM (64% vs. 84%, respectively).8 In Chapter 5 we reported 
on 26 patients who died from GTN, of whom 19 patients were found to have a 
post-term choriocarcinoma. In our study, two patients with post-term GTN would 
have been classified as low-risk according to the FIGO 2000 criteria, and would 
subsequently have been treated with single-agent MTX. Lok et al. reported on MTX 
resistance in 75% of patients with post-term choriocarcinoma primarily treated with 
MTX. A subgroup of patients in which single-agent chemotherapy would be a safe 
alternative could not be determined. Additionally, an overall survival rate of 85% was 
found in patients with post-term choriocarcinoma, which is comparable to survival 
rates of high-risk disease in general.9 In chapter 6 we showed that 14 out of the 17 
patients treated with EMACP for post-term GTN went into remission (82.4%), and 28 
out of the 38 patients with an antecedent term pregnancy (73.7%) treated with 
EMA/CO. This was lower than the overall disease remission rate that was observed 
with EMACP (91.6%) and EMA/CO (85.4%). We propose an increasing role for term 
114 | Chapter 8
antecedent pregnancy in the FIGO prognostic scoring system. This might be manifested 
by allotting four points instead of the two points that are currently allotted to patients 
with a previous term pregnancy.
Low-risk GTN: three consolidation courses of MTX 
Regarding the management of low-risk patients with two or three consolidation 
courses of MTX (Chapter 4), we reported that 4.0% of patients relapsed after MTX 
treatment with three consolidation courses after normalisation of hCG levels, 
whereas 8.3% of patients relapsed after MTX treatment with two consolidation 
courses. Although other factors might have influenced the difference in relapse 
rates found in this study, we stated that three courses of consolidation chemotherapy 
may be preferable to two in the treatment of low-risk GTN in order to decrease the 
risk of development of disease relapse. Obviously, a randomised prospective study 
to confirm our findings would be desirable. In general, caution needs to be exercised 
with retrospective studies because bias is more common than in prospective studies, 
and it may not always be possible to retrieve information on all parameters. However, 
retrospective studies have the ability to address research questions on diseases of 
low incidence, which would require extremely large cohorts in prospective studies 
and thus require a long time to complete. Therefore our results provide the best 
available data regarding the possible need for three as opposed to two courses of 
consolidation therapy in this disease setting. Results of our study were presented to 
the Dutch Working Party on Trophoblastic Disease and we proposed to alter the 
national guideline concerning the management of low-risk GTN from two to three 
consolidation courses of MTX after normalisation of the serum hCG concentration. 
High-risk GTN: use of normograms for prediction of resistance  
to chemotherapy
Previously, our group developed a normogram for the regression of hCG concentrations 
during the treatment of low-risk GTN with MTX to identify resistance to MTX in an 
early stage.10 This normogram has now been adopted by the Dutch Working Party 
for Trophoblastic Disease and is used by the advisory body of the Working party in 
their consultation on patients that are presented to them from throughout the 
country. Early identification of patients resistant to multi-agent chemotherapy 
seems even more important, since these patients are at risk for a fatal outcome, and 
further treatment options are limited. In Chapter 7 we constructed two normograms for 
the prediction of resistance to EMA/CO chemotherapy and demonstrated examples 
of patients that could in an early stage have been predicted as developing resistance 
to treatment. In addition, we showed that normograms for hCG regression under 
multi-agent treatment differed depending on the indication for multi-agent chemo- 
therapy, with much higher initial hCG values in the group of patients with primary 
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high-risk disease compared to those treated with EMA/CO for MTX resistant disease. 
These normograms still need to be validated in a larger cohort of patients. Subsequently, 
these normograms can be of great value in the decision making of patients treated 
with EMA/CO chemotherapy, bringing forward the vitally important switch to EMA/
EP chemotherapy in patients that will not be cured with EMA/CO. However, the 
normograms should only be used by gynaecologists experienced in the field of GTN.
Adjustments in the organisation of management of GTN
Centralisation
Besides improving the management of GTN by scientific research, much can be 
gained by  adjustments in the organisation of management of GTN and GTD in 
general. Since the incidence of GTD is low, most general pathologists, gynaecologists 
and medical oncologists do not see many patients with GTN, which makes it difficult 
to build up expertise in this particular disease. We propose future referral of all 
hydatidiform moles to one of four yet to be assigned referral centres for further 
evaluation and determination of management in case of development of low-risk 
GTN. High-risk GTN patients would preferably have to be referred to one referral 
hospital. This is somewhat similar to the organisation of care of patients with GTD 
in the UK, where the first national service for GTD was established through a 
combined agreement of the Royal College of Obstetricians and Gynaecologists and 
the Department of Health’s National Commissioning Group. Since 1973, all women 
with hydatidiform mole or other forms of GTD have been registered with one of 
three centres for hCG monitoring and, if subsequent treatment is necessary, they 
are treated at the Sheffield Trophoblastic Disease Centre (Sheffield, UK) or Charing 
Cross Hospital Trophoblast Disease Centre (London, UK).11 
Uniformity in scoring systems
To facilitate and improve the comparison of data from various hospitals and various 
countries, different scoring systems to classify GTN should be harmonised.12 
Comparison of results between countries or to international literature is difficult 
due to the use of a classification system in the Netherlands that is different from the 
FIGO prognostic scoring system. Ngan previously stated that all physicians treating 
GTN should use the FIGO 2000 scoring system, so that data can be compared among 
different centres.13 Retrospective allocation of the FIGO score is often difficult. Since 
the Dutch classification system does not include all items that are included in the 
FIGO prognostic scoring system, not all items required to retrospectively determine 
the FIGO score are recorded for the Dutch patients. Often data on the items ‘number 
of  metastases’ and ‘largest tumour size’ cannot be retrieved. In 1986, Dijkema et al. 
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made a comparison of the ability of the Dutch classification and the scoring systems 
developed by Bagshawe and Goldstein to predict the effect of primary treatment 
with MTX (n=37).14 They found there was hardly any difference in specificity and 
prognostic value between the Bagshawe score and the Dutch classification, but a 
somewhat lower sensitivity in the Dutch classification system was observed. This 
illustrates the need for uniformity in application of a scoring system. In the 
Netherlands we should adopt the internationally used FIGO scoring system. 
Preferably this would be a next (modified) version of the scoring system with a more 
prominent role assigned to an antecedent term pregnancy as a poor prognostic 
factor. This would simplify the comparison of patients using FIGO scores, which is of 
great importance in diseases with a low incidence such as GTD to enable large 
multi-centre studies with sufficient numbers of patients.
More uniform hCG measurement
Centralisation of care might result in more adherence to the guidelines in the 
management of patients and clinical expertise can be extended. In addition, it 
would dramatically reduce the number of different hCG assays used leading to more 
uniformity in the hCG measurements. As stated previously, the Nijmegen radioim-
munoassay (RIA) detects intact hCG and free-beta subunit.15 Most laboratories use 
sandwich-type assays as this type of assay can be performed automatically on a 
random access platform and is thus less labour-intensive, facilitating a high 
throughput of samples. Sandwich assays in general are highly specific and less 
molecular forms of  hCG are detected than with a RIA. In patients with GTD, the 
predominant molecular form(s) of hCG present in blood might be different from the 
intact hCG molecule. Therefore, it is highly recommended to use an hCG assay that 
detects different/most forms of hCG for diagnosis and follow-up of GTD patients.16 
International collaboration
On an international level, in 2009 the European Organisation for the Treatment of 
Trophoblastic Disease (EOTTD) was founded in order to improve management and 
subsequent registration of GTD in Europe.17 In May 2010 the first meeting of the 
EOTTD was held in Lyon where over 50 gynaecologists, oncologists and clinical 
chemists where gathered. An inventory was made of the current organisation of 
care around GTD patients in different European countries, including the estimated 
disease incidence, registration systems and management of GTD. In addition, an 
agreement was signed to underline the importance of raising attention for GTD. 
Participants from 15 different countries reached a consensus on the need for 
education, taking steps toward centralisation of clinical management and 
registration of GTD cases in every participating country. To accomplish this, one of 
the goals of the EOTTD is to connect a gynaecologist, oncologist and expert 
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pathologist on gestational trophoblastic disease in every country, in order to be able 
to build clinical expertise on GTD, which would further improve outcomes in the 
management of the disease. In the long run, this would ideally also lead to uniformity 
in the type of hCG assay used by laboratories in these countries. An external quality 
assessments program should become available to harmonise the hCG assay results. 
A working party on hCG with prominent members was established to formulate 
further advice on the preferred hCG assay. 
Better registration for research
Currently, registration in the Dutch Central Registry for Hydatidiform Moles 
(DCRHM) is not obligatory and therefore not all patients in the Netherlands will be 
registered. Due to the possibility of an underestimation of the number of patients, 
to establish the incidence of GTD in the Netherlands (Chapter 2) we used PALGA 
(Pathologisch Anatomisch Landelijk Geautomatiseerd Archief), a unique nationwide 
network and archive that has complete coverage of all histopathological and cyto-
pathological diagnoses made in the Netherlands.18 Also, from many patients 
registered in the DCRHM no serum hCG concentrations are available obtained using 
the hCG RIA of the central laboratory of the working party. In developing the models 
for prediction of  post-molar GTN (Chapter 3) and prediction of resistance to 
multi-agent chemotherapy in high-risk patients (Chapter 7), this resulted in small 
numbers of patients eligible for the study. Centralisation of care would facilitate and 
simplify a more complete registration of GTD patients and collection of serum and 
tissue for research purposes.
Future  research
The findings in this thesis offer new possibilities for further research. First, to gather 
support for a more uniform classification of patients diagnosed with GTN, for 
instance by application of the FIGO 2000 classification system instead of the Dutch 
classification system, it would be of high interest to note in what proportion of 
patients treatment would be different using one classification system or the other. 
The collection of patients that would be classified and thus treated differently 
according to the FIGO 2000 system compared to the current Dutch classification 
system, and an analysis of the outcome of these patients would be valuable. This 
might also provide a solid ground for our proposal to attach more importance to an 
antecedent term pregnancy in the next version of the FIGO scoring system. 
 Secondly, up to now most of our efforts to predict GTN at an early stage of 
the disease has focused on serum hCG as a tumour marker.19-21 It is well known 
that complete and partial hydatidiform moles are genetically distinct, but both 
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overexpress paternal genes. Clues to the causative genes in GTD have come from 
linkage studies in families with repetitive molar pregnancies, in which the mole is 
biparental in origin but pathologically indistinguishable from other complete 
HMs.22-25 In these rare cases, mutations of the NLRP7 gene on chromosome 19 are 
thought to cause the disease in some patients. However, since not all familial cases 
could be explained by a mutation in this gene, other/more genes are probably 
involved. Besides using genetics in trying to understand more about the origin of 
HM, it would be interesting to explore possibilities of using genetics in the prediction 
of GTN. 
 In Chapter 6 we compared the efficiency, toxicity and survival rate of EMA/CO 
and EMACP in the treatment of high-risk GTN. Future chemotherapeutic agents 
might be found in the group of taxanes, such as paclitaxel and docetaxel.26-28 
Previous literature suggests that paclitaxel contributes significantly to the treatment 
of choriocarcinoma, mostly in the setting of tumours resistant to second-line EMA/
EP therapy.26;28 The integration of agents such as paclitaxel has not yet been subject 
to a randomised trial. As previously stated, randomised controlled trials can only be 
realised by means of international collaboration and equal risk classification of 
patients to ensure sufficient numbers of patients. Until then, a description of a large 
series of patients treated with a regimen containing paclitaxel or docetaxel would 
provide us with further information on the value of these agents in the management 
of GTN.
 Finally, external validation of the normograms for patients with high-risk GTN 
(Chapter 7) in a larger cohort of patients is required before these tools can be applied 
in clinical practice. More patients that showed progression on EMA/CO are needed 
to investigate what proportion of patients not showing disease remission on EMA/
CO can be predicted in an early phase of their treatment.
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Summary
Chapter 1 describes the background and introduces research parameters of the 
studies performed within this thesis. Gestational trophoblastic neoplasia (GTN) 
represents the malignant forms of gestational trophoblastic disease (GTD), and 
comprises invasive hydatidiform moles that do not resolve spontaneously, chorio-
carcinoma, placental site trophoblastic tumour (PSTT) and the rare epithelioid tropho- 
blastic tumour (ETT). Once the diagnosis of GTN is made, thorough assessment of 
the extent of disease as well as an evaluation for risk factors should be performed, 
in order to classify patients into low-risk or high-risk disease. Treatment of low-risk 
disease consists of single-agent chemotherapy, mostly methotrexate (MTX). 
High-risk patients are considered to be at high risk of developing resistance to 
single-agent MTX, and are therefore treated with multi-agent chemotherapy, mostly 
EMA/CO (etoposide, MTX and actinomycin D, alternating with cyclophosphamide 
and vincristine). Research parameters in this thesis include disease incidence, 
prediction of post-molar GTN and resistance to multi-agent chemotherapy, and 
evaluation of the treatment of low- and high-risk GTN.
 The reported incidence of GTD varies widely in different regions of the world. In 
chapter 2 we determined the incidence and time trends of GTD in the Netherlands 
using population-based data obtained from PALGA, a national archive containing all 
histopathology reports in the Netherlands. Overall incidence rates of hydatidiform 
mole (HM), choriocarcinoma and PSTT were 1.34 per 1,000 deliveries, 3.1 per 100,000 
deliveries, and 1.0 per 100,000 deliveries, respectively. The incidence of GTD in the 
Netherlands increased significantly from 1995 to 2008. This can partially be 
explained by increased maternal age and increased proportion of live births of Asian 
descent. Part of the increase might result from improved diagnostic techniques. 
However, these factors do not seem to account for the total observed increase and 
part of the increase therefore remains unexplained.
 Currently, serum human chorionic gonadotrophin (hCG) follow-up after evacuation 
of hydatidiform moles is essential to identify patients requiring chemotherapeutic 
treatment. Chapter 3 described a model based on linear regression of post-evacuation 
serum hCG concentrations for the prediction of post-molar GTN. The slopes of the 
linear regression lines of the first three log-transformed serum hCG and free beta 
hCG values were calculated. Receiver operating characteristic curves were 
constructed to calculate Areas Under Curve (AUCs). The slope of free beta hCG 
seems to be a better predictor for post-molar GTN than the slope of hCG. Post-molar 
GTN could be predicted in 69% of patients at 97.5% specificity. Thirty-eight percent 
of post-molar GTN patients could be predicted prior to diagnosis according to the 
FIGO 2000 criteria. Although this model needs further validation for different assays, it 
seems a promising way to predict the more aggressive cases of post-molar GTN.
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 MTX alternating with folinic acid is a commonly used treatment regimen for 
low-risk GTN. In the Netherlands, two courses of MTX are administered after 
normalisation of serum hCG levels (consolidation courses), whereas in the United 
Kingdom, three consolidation courses are given. In chapter 4 we compared in a 
retrospective setting relapse rates of women completing MTX therapy for low-risk 
GTN in the Netherlands and the UK. In 4.0% of patients relapse occurred after MTX 
treatment with three consolidation courses, whereas 8.3% of patients relapsed after 
MTX treatment with two consolidation courses (p=0.006). Although patients from 
the Netherlands had a higher level of hCG and more patients had metastases before 
the start of treatment, the number of courses of MTX to achieve a normal hCG did 
not differ significantly between patients from the Netherlands and the UK. We 
concluded that although other factors might have influenced the observed 
difference in relapse rates, three courses of consolidation chemotherapy may be 
preferable to two in the treatment of low-risk GTN in order to decrease the risk of 
disease relapse. A prospective randomised study would be required to confirm these 
findings.
 In chapter 5 we described fatal cases of GTN over four decades in the Netherlands 
and evaluated whether treatment was given according to the protocol at the time of 
diagnosis and aimed to reveal possible implications for future management. Data 
from patients who died from GTN from 1971 to 2011 were obtained from the DCRHM 
and the Dutch Working Party on Trophoblastic Disease. Twenty-six patients died 
from GTN. In five cases GTN developed after a hydatidiform mole and in 19 cases 
GTN occurred following term pregnancy. Half the number of patients died between 
1971-1980 (n=13) when patients were not yet classified as having low- or high-risk 
disease and were thus not yet treated accordingly. The yearly number of patients 
that died from GTN decreased considerably over the last four decades. Twelve out of 
17 patients who were initially treated with MTX had high-risk disease according to 
the current Dutch risk classification and should therefore have received combination 
chemotherapy. We concluded that appropriate risk classification is essential to start 
optimal initial therapy and to prevent therapy resistance. Patients with post-term 
choriocarcinoma represented a large proportion of the deceased patients and we 
proposed that these patients, as in Dutch classification system, are considered as 
having high-risk disease.
 In chapter 6 we evaluated the efficacy and safety of cisplatin-based combination 
chemotherapy (etoposide, MTX, actinomycin D, cyclophosphamide and cisplatin; 
EMACP) compared to the EMA/CO schedule for the treatment of high-risk GTN. 84 
patients treated with 330 courses of EMACP and 103 patients treated with 688 
courses of EMA/CO were identified from the databases of the DCRHM and the 
Dutch Working Party on Trophoblastic Disease. The remission rate was not 
significantly different with EMACP (91.6%) or with EMA/CO (85.4%). The median 
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number of courses to achieve normal serum hCG concentrations in patients treated 
with EMA/CO for single-agent resistant disease and primary high-risk disease were 
3 and 5 courses, compared to 1.5 and 3 courses of EMACP, respectively. Patients 
treated with EMACP more often developed fever, renal toxicity, nausea and diarrhoea 
compared to patients treated with EMA/CO. Patients treated with EMA/CO more 
often had anaemia, neuropathy and hepatotoxicity. The number of patients that 
developed secondary tumours was comparable in EMA/CO (3.9%) and EMACP 
(3.6%). Dose reduction occurred in 39 EMACP courses (11.8%) and in 60 (8.7%) EMA/
CO courses (p=0.119). 45 courses of EMACP were delayed (13.6%), compared to 33 
(4.8%) EMA/CO courses (p<0.001). We concluded that EMACP combination 
chemotherapy is an effective treatment for high-risk GTN. However, the remission 
rate of EMACP was not significantly higher compared to EMA/CO, and although less 
courses of EMACP were required to achieve disease remission, the difference in 
duration of chemotherapeutic treatment was only slightly shorter with EMACP. 
Short term toxicity was alternating more common in EMACP and EMA/CO, whereas 
long-term toxicity was not different between both regimens. Therefore cisplatin-
based chemotherapy in the form of EMACP does not seem preferable over EMA/CO 
as first-line treatment of high-risk GTN.
 Early identification of patients with high-risk GTN resistant to multi-agent 
chemotherapy is highly important since they are at risk for a fatal outcome. In 
chapter 7 we presented a normogram for hCG regression in patients with high-risk 
GTN successfully treated with multi-agent chemotherapy in order to predict 
treatment resistance. Using this normogram, patients could be predicted in an early 
stage as developing resistance to treatment as illustrated with examples. We 
showed that normograms for hCG regression under multi-agent treatment differed 
depending on the indication for multi-agent chemotherapy, with much higher initial 
hCG values in the group of patient with primary high-risk disease compared to those 
treated with EMA/CO for MTX resistant disease. 
 In chapter 8, we summarised the main findings of the studies in this thesis, we 
discussed methodological issues, addressed the importance of the organisation of 
the management of GTN, and postulated ideas for future research.
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Samenvatting
In hoofdstuk 1 beschreven we de achtergrond en de onderzoeksparameters van de 
studies die in dit proefschrift werden uitgevoerd. Trofoblasttumoren omvatten de 
maligne vormen van trofoblastziekte, en bestaan uit invasieve mola hydatidosa die 
niet spontaan in regressie gaan, choriocarcinomen, “placental site trophoblastic 
tumour” (PSTT) en de uiterst zeldzame epithelioide trofoblast tumoren (ETT). Als de 
diagnose trofoblasttumor gesteld wordt, is onderzoek naar de uitgebreidheid van de 
ziekte nodig, alsmede een evaluatie van risicofactoren, zodat patiënten kunnen 
worden ingedeeld als hebbende laag- of hoog-risico tumoren. De behandeling van 
laag-risico tumoren bestaat uit monochemotherapie, veelal in de vorm van 
methotrexaat (MTX). Van hoog-risico tumoren wordt aangenomen dat ze een 
hoog-risico hebben om resistentie te ontwikkelen tegen MTX, en worden daarom 
behandeld met polychemotherapie. Internationaal is de meeste ervaring opgedaan 
met het EMA/CO-schema (etoposide, MTX en actinomycine D, afgewisseld met 
cyclofosfamide en vincristine). In dit proefschrift worden de ziekte incidentie, het 
voorspellen van het ontstaan van trofoblasttumoren na een mola hydatidosa en het 
voorspellen van resistentie tegen polychemotherapie, alsmede de behandeling van 
laag- en hoog-risico trofoblasttumoren bestudeerd.
 Er is grote variatie in de gerapporteerde incidentie van trofoblastziekten in 
verschillende delen van de wereld. In hoofdstuk 2 beschreven we de incidentie en 
trends in de tijd van trofoblastziekten in Nederland met behulp van populatie 
gebaseerde data die werd verkregen uit PALGA, een landelijke databank met alle 
pathologie-uitslagen in Nederland. De totale incidentie van mola hydatididosa, cho-
riocarcinoma en PSTT was respectievelijk 1.34 per 1000 bevallingen, 3.1 per 100,000 
bevallingen, en 1.0 per 100,000 bevallingen. De incidentie van trofoblastziekten in 
Nederland nam significant toe van 1995 tot 2008. Dit kan deels worden verklaard 
door een toegenomen maternale leeftijd en een toegenomen aandeel van levendge-
borenen met minimaal één ouder van Aziatische afkomst. Een deel van de toename 
kan mogelijk ook het gevolg zijn van verbeterde diagnostische technieken. Deze 
factoren verklaren echter niet de gehele toename in incidentie en een deel van de 
geobserveerde stijging blijft daarom onverklaard.
 Momenteel is het vervolgen van het serum humaan choriongonadotrofine (hCG) 
na de curettage van een mola hydatidosa essentieel om patiënten te identificeren 
bij wie chemotherapeutische behandeling voor persisterende trofoblastziekte 
noodzakelijk is. In hoofdstuk 3 beschreven we een model op basis van de lineaire 
regressie van serum hCG concentraties verkregen in de eerste weken na curettage 
voor het voorspellen van het ontstaan van persisterende trofoblastziekte. De helling 
van de lineaire regressie lijnen van de eerste drie log-getransformeerde serum hCG 
en vrij bèta hCG waarden werden berekend. Receiver Operating characteristic (ROC) 
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Curves werden geconstrueerd en de Areas Under Curve (AUCs) berekend. De helling 
van vrij bèta hCG bleek een betere voorspeller voor persisterende trofoblastziekte 
dan de helling van het hCG. Persisterende trofoblastziekte kon worden voorspeld bij 
69% van de patiënten met 97.5% specificiteit. Achtendertig procent van de patiënten 
die persisterende trofoblastziekte ontwikkelde kon worden voorspeld vóór de 
diagnose volgens de FIGO 2000 criteria. Hoewel dit model gevalideerd moet worden 
voor verschillende hCG assays, lijkt het een veelbelovende manier om de meer 
agressieve gevallen van persisterende trofoblastziekte te voorspellen.
 Methotrexaat met folinezuur is het meest gangbare behandelschema voor laag- 
risico trofoblasttumoren. In Nederland worden na normalisatie van het serum hCG 
nog twee kuren  MTX gegeven (consolidatie kuren), terwijl in het Verenigd Koninkrijk 
drie consolidatie kuren worden gegeven. In hoofdstuk 4 vergeleken we in een 
retrospectieve setting het percentage recidief trofoblasttumoren bij vrouwen die 
succesvol behandeld zijn met MTX voor een laag-risico trofoblasttumor in Nederland 
en in het Verenigd Koninkrijk. In 4.0% van de patiënten kwam een recidief trofo-
blasttumor voor na MTX behandeling met drie consolidatie kuren, terwijl in 8.3% 
van de patiënten die behandeld werden met twee consolidatiekuren een recidief 
trofoblasttumor werd geconstateerd. (p=0.006). Hoewel de Nederlandse patiënten 
hogere hCG concentraties hadden en meer patiënten metastasen hadden voor de 
start van de behandeling, verschilde het benodigde aantal kuren MTX om een 
normaal hCG te verkrijgen niet tussen de patiënten uit Nederland en uit het Verenigd 
Koninkrijk. We concludeerden dat hoewel andere factoren dan de consolidatiekuren 
mogelijk het geobserveerde verschil in percentage recidief trofoblasttumor kunnen 
hebben beïnvloed, drie kuren consolidatie chemotherapie mogelijk te prefereren is 
boven twee consolidatiekuren in de behandeling van laag-risico trofoblasttumoren 
om zo de kans op een recidief trofoblasttumor te verkleinen. Een prospectieve ge-
randomiseerde studie is nodig om deze bevindingen te bevestigen.
 In hoofdstuk 5 beschreven we de patiënten overleden aan een trofoblasttumor 
gedurende vier decennia in Nederland en evalueerden of behandeling in overeen-
stemming was met het protocol ten tijde van de diagnose, en probeerden hieruit 
mogelijke implicaties voor toekomstig beleid te formuleren. Data van patiënten die 
overleden als gevolg van een trofoblasttumor van 1971 tot en met 2011 werden 
verkregen uit de CMRN en de Werkgroep Trofoblast Tumoren. Zesentwintig patiënten 
overleden als gevolg van een trofoblasttumor. Bij vijf patiënten ontstond de trofo-
blasttumor na een mola hydatidosa en bij 19 patiënten ontstond deze na een 
voldragen zwangerschap. De helft van de patiënten overleed tussen 1971-1980 (n=13) 
voordat trofoblasttumoren werden geclassificeerd in laag- of hoog-risico tumoren 
en dus ook nog niet zodanig behandeld werden. Het jaarlijkse aantal patiënten dat 
overleed aan een trofoblasttumor daalde aanzienlijk gedurende de laatste vier 
decennia. Twaalf van de 17 patiënten die initieel behandeld werden met MTX hadden 
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een hoog-risico tumor volgens de huidige Nederlandse risico classificatie en zouden 
daarom nu behandeld zijn met  polychemotherapie. We concludeerden dat een 
juiste risicoclassificatie essentieel is om te kunnen starten met een optimale 
behandeling en therapieresistentie te voorkomen. Patiënten met een trofoblasttu-
mor na een voldragen zwangerschap vormden een groot deel van de overleden 
patiënten en wij stelden voor dat deze tumoren, net zoals in het Nederlandse 
classificatie systeem, worden beschouwd als hoog-risico tumoren.
 In hoofdstuk 6 vergeleken we de werkzaamheid en veiligheid van poly-chemo-
therapie met cisplatine (etoposide, MTX, actinomycine D, cyclofosfamide en 
cisplatine; EMACP) met het EMA/CO schema voor de behandeling van hoog-risico 
trofoblasttumoren. De 84 patiënten die samen werden behandeld met 330 kuren 
EMACP en de 103 patiënten die werden behandeld met 688 kuren EMA/CO werden 
geselecteerd uit de databases van de CMRN en de Werkgroep Trofoblast Tumoren. 
Het percentage patiënten dat in complete remissie kwam was niet significant 
verschillend voor patiënten die werden behandeld met EMACP (91.6%) of met EMA/
CO (85.4%). Het mediane aantal kuren om tot een normale serum hCG concentratie 
te komen was 3 bij patiënten die met EMA/CO werden behandeld wegens MTX 
resistentie en 5 kuren bij patiënten met een primair hoog-risico trofoblasttumor. Bij 
patiënten die werden behandeld met EMACP was dit respectievelijk 1.5 en 3 kuren. 
Patiënten die werden behandeld met EMACP ontwikkelden vaker koorts, renale 
toxiciteit, misselijk en braken en diarree vergeleken met patiënten die werden 
behandeld met EMA/CO. Patiënten die werden behandeld met EMA/CO hadden 
vaker last van anemie, neuropathie en hepatotoxiciteit. Het aantal patiënten dat 
secundaire tumoren ontwikkelde was vergelijkbaar tussen patiënten behandeld met 
EMA/CO (n=4; 3.9%) en EMACP (n=3; 3.6%). Dosis reductie was noodzakelijk bij 39 
EMACP kuren (11.8%) en bij 60 (8.7%) EMA/CO kuren (p=0.119). 45 EMACP kuren 
werden uitgesteld (13.6%), vergeleken met 33 (4.8%) EMA/CO kuren (p<0.001). We 
concludeerden dat polychemotherapie in de vorm van EMACP een effectieve 
behandeling is voor hoog-risico trofoblasttumoren. Echter, het percentage patiënten 
dat in complete remissie ging met EMACP was niet significant hoger vergeleken met 
EMA/CO, en hoewel er minder kuren EMACP nodig waren om remissie van de tumor 
te bereiken, was het verschil in duur van de chemotherapeutische behandeling 
slechts enigszins korter met EMACP. Korte termijn bijwerkingen kwamen afwisselend 
vaker voor  bij EMACP and EMA/CO, terwijl het voorkomen van lange termijn 
bijwerkingen niet verschilde tussen beide schema’s. Daarom heeft chemotherapie 
op basis van cisplatine in de vorm van EMACP, geen bewezen meerwaarde boven 
EMA/CO in de behandeling van patiënten met hoog-risico trofoblasttumoren. 
 Vroege identificatie van hoog-risico trofoblasttumoren die resistentie hebben 
ontwikkeld tegen polychemotherapie is van groot belang, aangezien deze patiënten 
het risico lopen op een fatale afloop. In hoofdstuk 7 presenteerden we een normo- 
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gram voor hCG regressie in patiënten met hoog-risico trofoblasttumoren die succesvol 
behandeld werden met polychemotherapie. We lieten met voorbeelden zien dat 
met behulp van dit normogram, resistentie ontwikkeling tegen EMA/CO al in een 
vroege fase van de behandeling voorspeld kon worden. We lieten zien dat de normo- 
grammen voor hCG regressie gedurende polychemotherapie verschilden afhankelijk 
van de indicatie voor polychemotherapie. Patiënten met primair hoog-risico tumoren 
hadden veel hogere hCG waarden bij start van EMA/CO dan patiënten die behandeld 
werden met EMA/CO voor MTX resistente tumoren. 
 In het laatste hoofdstuk vatten we de belangrijkste bevindingen van de studies 
in dit proefschrift samen, we bespraken methodologische discussiepunten, we 
behandelden het belang van de organisatie van zorg van trofoblasttumoren, en 
deden suggesties voor toekomstig onderzoek.
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stoppen, later alsnog starten is veel moeilijker”. Bedankt voor alle kansen, en dat jullie 
deur echt altijd open staat. Jullie stabiele basis heeft mij gebracht waar ik nu sta. 
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Charlotte Lybøl werd geboren op 8 juni 1984 in het Achterhoekse Sint Jozefziekenhuis 
te Doetinchem, en groeide op in het nabijgelegen Etten. Zij volgde het profiel Natuur 
en Gezondheid aan het Almende College locatie Isala te Silvolde. In 2002 behaalde zij 
haar gymnasium diploma en kon meteen beginnen aan de studie geneeskunde aan 
de toenmalige Katholieke Universiteit Nijmegen. Tijdens het reguliere co-schap 
gynaecologie in het Slingeland ziekenhuis te Doetinchem werd haar interesse voor 
de gynaecologie gewekt. Een wetenschappelijke stage in het UMC St. Radboud op 
de afdeling Verloskunde en Gynaecologie (pijler gynaecologische oncologie) onder 
leiding van Prof. Dr. Leon Massuger naar de pathologie van het ovariumcarcinoom 
leidde er toe dat zij na het arts-examen in juni 2009 kon starten aan het promotie-
onderzoek naar trofoblastziekten. De samenwerking tussen de afdelingen Verloskunde 
en Gynaecologie (Prof. dr. Leon Massuger) en  Laboratoriumgeneeskunde (Prof. Dr. 
Fred Sweep en dr. Chris Thomas), later versterkt door de afdeling Medische Oncologie 
(dr. Petronella Ottevanger) leidde tot de studies die resulteerden in dit proefschrift. 
Sinds juni 2012 is Charlotte met veel plezier werkzaam als ANIOS op de afdeling 
Verloskunde en Gynaecologie van het Canisius Wilhelmina Ziekenhuis te Nijmegen. 
Per 1 april 2013 start zij met de opleiding tot gynaecoloog in het Jeroen Bosch 
Ziekenhuis te ’s Hertogenbosch (opleider dr. H.P. Oosterbaan).
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